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Abstract
Drug absorption, elimination and effect may be influenced by many factors including
type of formulation, particle size, dissolution and by the presence ofother drugs or food
and fluid ingestion. The influence of some of these factors on the absorption and effect
offrusemide and bumetanide have been investigated in the present studies.
The effect of food on the absorption of oral frusemide (40 mg) was determined in 8
healthy volunteers. Food significantly reduced peak plasma concentrations (2.35 ± 0.49
versus 0.51 ± 0.19 mg/1) and delayed the time to peak. The bioavailability of frusemide
was also significantly reduced from 76 % fasting to 43 % after food. The study was then
repeated in 9 healthy volunteers using oral bumetanide (2 mg) given with and without
food. The peak concentration was reduced after food (96.9 ± 15.1 versus
36.1 ± 11,5 pig/1) and the time to peak concentration delayed. However the mean
bioavailability of bumetanide was not significantly reduced by food. A survey carried
out in two medical wards within the Edinburgh Royal Infirmary then provided
information on the general use of frusemide and bumetanide and showed that most of the
patients were taking a single oral dose ofdiuretic with or in close proximity to breakfast,
a situation which could potentially alter diuretic absorption and effect. Consequently,
the effect ofhospital breakfast on the absorption and efficacy offrusemide was studied in
10 medical inpatients. However when frusemide was administered 2 hours after
breakfast, no significant improvement in area under the plasma concentration-time
curve, urinary recovery of frusemide or total natriuretic and diuretic response was
found.
The pharmacokinetics of frusemide were compared in 8 healthy volunteers following
oral administration of single doses of 10, 40 and 80 mg. Peak plasma concentrations,
areas under the plasma concentration time curves and amounts excreted, normalised to
40 mg, were not significantly different. Over this dose range there was no significant
dose-dependent effect on frusemide absorption.
The effects ofpenicillin on frusemide renal secretion and diuretic effect were studied in 8
healthy volunteers. Penicillin significantly reduced the renal clearance of frusemide
(103.0 ± 15.9 to 83.6 ± 17.4 ml/min), but had no effect on the area under the plasma
concentration-time curve, total urinary recovery of frusemide or on the time course and
magnitude ofnatriuresis and diuresis.
Finally, the time course of frusemide delivery to the active site has been suggested to be
an independent determinant of overall response. The kinetic and the dynamic effects of
the same total dose of frusemide (40 mg) administered as a single dose and as repeated
doses over 8 h were compared in 8 healthy volunteers. The average area under the
plasma concentration-time curve (2.89 ± 0.66 versus 2.25 ± 0.32 mg.h/1) and total
urinary recovery of frusemide (1 8.3 ±3.3 versus 16.4 ± 3.0 mg) were significantly lower
following the repeated doses. However despite less drug being delivered to the active
site, no significant differences were found in total sodium and water excretion compared
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Gastrointestinal drug absorption may be influenced by many factors including degree of
ionisation, formulation, particle size, dissolution, presence of other drugs and food or
fluid ingestion (Prescott, 1969; Rowland and Tozer, 1980; Welling 1977a, b, 1984). All
these factors may contribute to variability in drug response. The influence of some of
these factors on the absorption , elimination and effect of frusemide and bumetanide are
investigated in the following studies.
Frusemide and bumetanide are diuretic and natriuretic agents belonging to the class of
loop diuretics (Ponto and Schoenwald, 1990; Ward and Heel, 1984). They are both
commonly used in the treatment ofoedematous states associated with cardiac, renal and
hepatic disease (Hammarlund-Udenaes and Benet, 1989; Johnson and Johnson, 1990).
Their pharmacokinetics have been studied extensively (Benet, 1979; Cutler and Blair,
1979; Johnson and Johnson, 1990; Ponto and Schoenwald, 1990; Ward and Heel,
1984).
Frusemide is an anthranilic acid derivative, 4-chloro-N-furfuryl-5-sulfamoylanthranilic
acid, with a molecular weight of 330.74 (Cutler and Blair, 1979). The structure of
frusemide is shown in Fig 1.1. The compound is unstable to light but stable in air. It is
soluble in methanol, acetone, acetonitrile and solutions of alkali hydroxides. Its pKa is
3.9 (Ponto and Schoenwald, 1990).
The first clinical studies with frusemide were carried out by Kleinfelder in 1963 (Cutler
and Blair, 1979) and revealed that this drug displayed the now well known
characteristics of its loop diuretic activity. In contrast to thiazide diuretics, it has a
shorter duration of action, steeper dose response curve and greater diuretic and
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Figure 1.1. Chemical structure of frusemide
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natriuretic response.
Frusemide is believed to exert its primary effect at the luminal surface of the ascending
limb of the loop ofHenle in the nephron (Burg, 1976; Chennavasin et al. 1979; Odlind,
1979; Odlind and Beermann, 1980). At this site approximately 20-30 % of the filtered
sodium chloride is reabsorbed by a Na/2C1/K cotransport system (Wittner et al. 1991).
Frusemide is thought to reversibly block this carrier system, thus reducing sodium
chloride reabsorption (Feig, 1986; Greger and Schlatter, 1983; Hendry and Ellory,
1988). The increased delivery of sodium to more distal sites of the nephron also
produces an increase in the exchange of sodium for potassium, leading to greater
potassium excretion. The resulting lowmedullary osmolality inhibits the reabsorption of
water by the kidney, producing a pronounced diuresis. Although the above action is
generally considered most important for the natriuretic response offrusemide (Seely and
Dirks, 1977), several studies suggested that frusemide may have an additional effect at a
more proximal site (Brenner et al. 1969; Burke et al. 1972; Knox et al. 1969; Puschett
and Goldberg, 1968; Stasoneta/. 1966). This site ofaction was evaluated more recently
using a lithium clearance technique (Beutler et al. 1992; Christensen etal. 1986, 1988).
There is evidence that renal lithium clearance reflects the delivery of sodium and water
out of the proximal tubule (Christensen et al. 1988; Thomsen, 1984). Intravenous
frusemide was shown to increase lithium clearance in animals and humans suggesting
that frusemide causes inhibition of sodium reabsorption in the proximal tubule (Beutler
etal. 1992; Christensen et al. 1986).
In addition to its natriuretic and diuretic action, frusemide produces an early vasodilator
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action in particular, a rise in peripheral venous capacitance (Dikshit etal. 1973; Johnston
et al. 1983). This extrarenal vascular effect occurs prior to any diuretic effect and is
dependent on sodium balance and renal function (Johnston el al. 1983). Inhibition of
prostaglandin production also appears to abolish any increase in venous capacitance
produced by frusemide (Bourland et al. 1977; Johnston et al. 1983). Frusemide also
reduces renal vascular resistance with a resultant increase in renal blood flow, the degree
ofwhich is proportional to the initial resistance (Ludens et al. 1968). During diuresis,
glomerular filtration rate increases (Passmore et al. 1989), decreases (Christensen et al.
1986) or remains unaltered (Dupont etal. 1988).
Plasma concentrations of angiotensin II, aldosterone and noradrenaline increase after
frusemide administration (Mackay et al. 1984; Sjostrom et al. 1988a,b; Wilcox et al.
1983). After intravenous administration, the increase is thought to be independent of
sodium loss and the reduction in plasma volume whereas the release after oral
administration seems to be related to cumulative sodium excretion (Francis et al. 1985;
Noda et al. 1982). The acute natriuresis of frusemide is succeeded by a period ofsodium
retention, a process referred to as acute tolerance (Andreasen et al. 1989; Hammarlund
etal. 1985; Wilcox et al. 1983). Since angiotensin II (Johnson and Malvin, 1977) and
aldosterone can increase renal sodium reabsorption (Kelly et al. 1983) it has been
suggested that the observed activation of the renin-angiotensin-aldosterone system may
contribute to the development ofacute tolerance (Sjostrom etal. 1988b).
In humans and animals, excretion ofurinary prostaglandins also increase after frusemide
administration (Abe et al. 1977; Dupont etal. 1988;Katayamae/a/. 1984; Passmore et
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al. 1989; Patak etal. 1979) and in the rat frusemide has been shown to directly stimulate
prostaglandin production in the thick ascending limb of the loop of Henle
(Miyanoshita et al. 1989). Since prostaglandins A and E exhibit natriuretic and diuretic
effects, they may play a role in the response to frusemide. Prostaglandin synthetase
inhibitors such as indomethacin have been shown to attenuate both the haemodynamic
and diuretic effects of frusemide in most experimental studies (Benet, 1979;
Chennavasin et al. 1980; Errikson et al. 1987; Greven and Farjam, 1988; Nies et al.
1983; Patak etal. 1975) but not all (Bailie*?/al. 1976; Data et al. 1978; Williamson etal.
1975).
Being a weak acid, frusemide is believed to reach its site ofaction in the loop ofHenle by
active secretion in the proximal tubule via the nonspecific organic acid pump (Calesnick
etal. 1966;Forrey etal. 1974;Odlind, 1979). This is supported by the fact that blockage
of the pathway by probenecid, a competitive inhibitor of the organic acid pump
(Cunningham et al. 1981), decreases the renal clearance and urinary excretion of
frusemide (Brater, 1978; Chennavasin et al. 1979; Homeida et al. 1977; Honari et al.
1977; Odlind and Beermann, 1980). This change causes a rightward shift in the
relationship between serum concentrations of frusemide and response while having no
effect on the relationship between urinary frusemide and response (Chennavasin et al.
1979), demonstrating that the response is related to the concentration of drug in the
urine as opposed to that in the plasma in normal man.
The oral absorption of frusemide in healthy volunteers is known to be erratic and is
subject to large inter- and intraindividual variation (Andreasen et al. 1982; Grahnen et
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al. 1984). The bioavailability from oral dosage forms is also highly variable with
reported values ranging from 20 - 84 % (Grahnen et al. 1984). The extent ofabsorption
is influenced by underlying disease processes, being decreased in renal disease and even
more erratic in heart failure (Brater et al. 1982a; Greither et al. 1979; Ponto and
Schoenwald, 1990). Absorption is also variably influenced by dosage form
(Hammarlund etal. 1984; Waller etal. 1988) and food (Beermann and Midskov, 1986;
Hammarlund et al. 1984; Kelly etal. 1973). Hammarlund et al (1984) and Waller etal
(1988) found differences in the rate of frusemide absorption between a tablet and
solution form, however the extent of absorption was similar. Kelly et al (1973) and
Hammarlund et al (1984) found no difference in the extent of absorption when
frusemide was administered with food. Hammarlund et al (1984) did find that food
delayed its absorption by approximately 60 minutes. On the other hand Beermann and
Midskov (1986) found that food reduced the bioavailability of frusemide by
approximately 30%.
It was suggested that the poor bioavailability could be due to poor solubility of
frusemide, gastric first pass metabolism (Lee et al. 1983) and possibly frusemide site
specific active absorption (Chungie/a/. 1979;Ritscheleta/. 1991).
One, two and three compartment models have been used to describe the plasma
concentration-time curves following intravenous administration of frusemide (Cutler
and Blair, 1979; Hammarlund etal. 1984; Kelly etal. 1973). However a 2-compartment
model is most often used due to the relativelyminor contribution ofthe third process to
the overall area under the plasma concentration time curve (Hammarlund-Udenaes and
7
Benet, 1989). Using this model the early distribution phase is quite rapid following an
intravenous dose and usually appears to be complete within 30 minutes (Cutler and
Blair, 1979)
Frusemide is extensively bound to plasma proteins (> 90 %), almost exclusively to
albumin (Andreasen and Jakobsen, 1974; Bowman, 1975; Cutler etal. 1974; Rane etal.
1978). The high degree of protein binding restricts the apparent volume ofdistribution
ofthe drug and values of4.6 -13.8 litres have been reported in healthy volunteers (Ponto
and Schoenwald, 1990).
A glucuronide metabolite of frusemide is excreted in the urine and faeces ( Ponto and
Schoenwald, 1990) however the fraction excreted in the urine varies, ranging from
2-25 % in healthy volunteers (Andreasen and Mikkelson, 1977; Andreasen etal. 1981;
RakhittTa/. 1987; Smith et al. 1980). Factors such as age, route of administration and
long term use may contribute to the variability (Andreasen and Mikkelson, 1977;
Beermann et al. 1975; Hammarlund-Udenaes and Benet, 1989). After intravenous
administration, between 6 and 18 % of the dose will eventually be eliminated in the
faeces of healthy subjects (Beermann et al. 1975). The site or sites of frusemide
metabolism are still unknown, although it has been suggested that the liver is probably
not the major site since there is no change in nonrenal clearance in patients with liver
disease (Fuller et al. 1981; Verbeeck etal. 1982). Also a study in dogs demonstrated
that neither the renal or nonrenal clearance of frusemide was changed when the entire
liver was removed and that urinary recovery of frusemide glucuronide remained
unchanged (Verbeeck et al. 1981). The kidney itself has been proposed as the site of
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glucuronidation (Rakhit etal. 1987;Vreeetal. 1995).
There is much debate over another potential metabolite, 4-chloro-5-sulfamoyl
anthranilic acid (CSA). Several investigators have argued that CSA is an analytical
artifact produced during extraction procedures (Benet, 1979; Smith et al. 1980). This
was due to the fact that some investigators failed to find CSA in the plasma and urine of
healthy volunteers and patients (Beermann etal. 1975; Branched a/. 1977; Kerremanse/
al. 1982; Smith et al. 1980) and that a major photodegradation product of frusemide
glucuronide had a similar retention time as CSA under certain analytical conditions
(Hammarlund-Udenaes and Benet, 1989). Smith et al (1980) were also able to produce
CSA from acid degradation of a frusemide stock solution as well as by employing the
acid extraction procedure detailed by Perez etal. (1979).
In healthy volunteers the elimination half-life of frusemide is usually in the range 30 - 120
minutes (Ponto and Schoenwald, 1990). Huang et al (1974) found an average half-life
of 9.7 h in patients with end stage renal disease. When compared to healthy volunteers,
the elimination half-life was longer or equivalent in patients with liver disease (Dreux et
al. 1979; Verbeeck et al. 1982) and the range reported in patients with congestive heart
failure is 50 - 330 minutes (Brater et al. 1982a).
In healthy and diseased subjects the systemic clearance of frusemide is generally
reported to be in the range 0.09 - 0.18 L/kg and renal and nonrenal processes generally
contribute equally (Benet, 1979). The relative contribution of the excretion processes is
influenced by age, disease and drug interactions (Ponto and Schoenwald, 1990).
Clearance reduces with age, probably due to declining renal function (Chaudry et al.
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1984;Kerremansefa/. 1983). Impaired renal function in patients with renal and cardiac
failure decreases the renal component of the systemic clearance of frusemide (Brater et
al. 1982a; Raneetal. 1978; Rose etal. 1976). Probenecid and indomethacin reduce the
renal clearance of frusemide by inhibiting its active secretion (Odlind and Beermann,
1980;Homeidar?/a/. 1977;Honari etal. 1977;Smithetn/. 1979, 1980).
The effectiveness of frusemide as a diuretic depends upon it reaching its site of action,
the renal tubules, unchanged (Brater, 1986). Approximately one-half to two-thirds ofan
intravenous dose or one-quarter to one-halfofan oral dose are excreted unchanged, the
difference being largely due to poor bioavailability from the oral route (Ponto and
Schoenwald, 1990).
Bumetanide (3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid) was first synthesised
in 1968 (Johnson and Johnson, 1990). Its structure is shown in Fig 1.2. Olesen et al
(1973) carried out the first clinical study which proved the usefulness of this drug in
patients with congestive heart failure and in the same year Feit et al {1973) developed a
sensitive gas liquid chromatography technique for its measurement. In healthy subjects
bumetanide is 40 - 70 times more potent than frusemide on a weight basis (Brater et al.
1981, 1983a;Daviese/o/. 1974; Ramsay etal. 1978).
Like frusemide, bumetanide is believed to exert its primary affect at the thick ascending
liinboftheloopofHenle(Bourkee/a/. 1973;Higashioe/«/. 1978;Lant, 1975). Itbinds
reversibly to the Na/2C1/K transporter complex at a protein binding site for chloride
(Hass and Forbush, 1987; Hass and McManus, 1983; Hedge and Palfrey, 1992). By this
reversible binding it inhibits sodium and chloride reabsorption. Bumetanide also
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Figure 1.2. Chemical structure of bumetanide
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reduces sodium reabsorption in the proximal tubule (Puschett et al. 1978; Staalsen and
Steiness, 1990), an action which seems to be independent of carbonic anhydrase
inhibition (Jayakumar and Puschett, 1977; Vogh and Langham, 1981). Bunietanide
causes less potassium loss than frusemide, for a given natriuresis, in healthy volunteers
(Branch c/o/. 1976;Hettiarachchie/a/. 1977; Ramsay et al. 1978).
Bumetanide enhances renal blood flow but has little effect on glomerular filtration rate in
man (Bourke et al. 1973; Olsen, 1975a). The renal blood flow effect occurs before
diuresis and is inhibited by indomethacin. It is therefore thought to involve
prostaglandins (Olsen, 1975 b). The observation that the pattern ofurinary excretion of
prostaglandin E is similar to that of enhancement of renal blood flow also suggests this
(Ward and Heel, 1984). Bumetanide, like other loop diuretics, also causes a several fold
increase in plasma renin activity in animals (Olsen and Ahnfelt-Ronne, 1976) and man
(Pedrinellieta/. 1980).
Absorption of bumetanide is rapid and almost complete following a single oral dose in
healthy volunteers (Marcantonio et al. 1982; Pentikainen et al. 1977). Using
14C-labelling or high performance liquid chromatography techniques, bioavailabilities
of 90 % or more have been recorded (Halladay et al. 1977; Pentikainen et al. 1977).
However lower values of approximately 80 % have also been reported (Brater et al.
1983a; Cook et al. 1988; Holazo etal. 1984). Bumetanide absorption also seems to be
unaffected by disease states (Bailie et at. 1987; Cook et al. 1988; Marcantonio et al.
1983) although slower absorption has been reported in patients with congestive heart
failure(Bratere/a/. 1982b).
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The oral bioavailability of bumetanide is therefore about 80 % compared with 50 % for
frusemide. This distinction is important when converting from intravenous to oral
administration. Changing from intravenous to oral dosing requires twice as much oral
frusemide, whereas equal doses are required for bumetanide (Brater, 1986). The time
course ofabsorption does not differ appreciably between the two diuretics (Brater et al.
1983a).
The plasma concentration time curves for bumetanide are most often described using a
2 compartment model (Bailie et al. 1987; Pentikainen et al. 1980) however
monoexponential and triexponential models have also been used (Davies et al. 1974;
Pentikainen et al. 1980). After intravenous administration in healthy subjects,
bumetanide has a rapid distribution phase followed by slower elimination with a half-life
of 1 - 1.5 h (Marcantonio et al. 1982; Pentikainen et al. 1977, 1980). The values
reported for the apparent volume of distribution of bumetanide in healthy volunteers
range from 9.5 to 35 litres (Davies et al. 1974; Dixon et al. 1976; Marcantonio et al.
1982). Its high degree ofprotein binding (> 90 %) is responsible for limiting the volume
ofdistribution (Walker et at. 1989).
In healthy volunteers, bumetanide is cleared from the plasma at an average rate of200 to
250 nil/min. Renal elimination constitutes about half of the clearance (Davies et al.
1974; Dixon et al. 1976; Halladay et al, 1977; Pentikainen et al, 1980) and hepatic
metabolism and biliary excretion account for the other half. Filtration ofbumetanide is
limited by the high degree of protein binding, however being a weak acid it is readily
secreted via the non specific organic acid pathway of the proximal tubule (Odlind et al.
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1983). Approximately 60-70 % of an intravenous dose is eliminated by this route and
appears unchanged in the urine (Cook et al. 1988; Lau et al. 1986: Marcantonio et al.
1982). The remainder is metabolised via oxidation of the n-butyl side chain to several
metabolites (Halladay et al. 1975; Pantikainen et al 1977) which are devoid of diuretic
activity (Schwartz, 1981). Most of the metabolites are subsequently excreted in the
urine, however a small amount is eliminated in the faeces via biliary excretion (Halladay
et al. 1975; Pentikainen et al. 1977, 1985). Differences therefore also exist in the
metabolism of frusemide and bumetanide. The site ofbumetanide metabolism is hepatic
whereas that of frusemide may be renal in origin (Beermann et al. 1975; Verbeeck et al.
1981). Also, bumetanide has several metabolites (Halladay etal. 1975), while frusemide
may only have a single glucuronide metabolite (Beermann et al. 1975; Smith et al.
1980).
From a pharmacokinetic perspective, the overall responses to frusemide and bumetanide
depend upon the total amount ofdrug delivered to the site ofaction, which will in turn be
determined by the dose, quantitative absorption and the capacity of the organic acid
transport pump to deliver drug from the blood into the urine (Brater, 1985). Any factor
which has the potential to decrease or increase absorption or excretion could therefore
alter diuretic response accordingly.
Food is one factor which exerts complex and often unpredictable influences on the oral
bioavailability of drugs (Beermann, 1979; Melander, 1978; Toothaker and Welling,
1980;Welling, 1977a, b, 1984). The outcome ofdrug food interactions is likely to be the
overall effect resulting from a number of factors related to the influence of food on
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gastrointestinal function or to a direct interaction between food components and the
drug (Welling, 1984).
The predominant effect of food is inhibition of stomach emptying due to feedback
mechanisms from receptors situated in the small intestine (Melander, 1978). Since most
drugs are predominantly absorbed from the small intestine (Rowland and Tozer, 1980),
changes in stomach emptying rate are likely to affect the rate of drug absorption.
Prolonged residence time in the acidic environment of the stomach may however have
other effects on drug absorption. It may delay the dissolution of acidic drugs and
accelerate dissolution of basic compounds (Welling, 1977 b). Ingestion of food
increases gastric secretion of hydrochloric acid, digestive enzymes and bile, hence
increased residence time may cause a reduction in the absorption efficiency for drugs
which are either acid labile or sensitive to such enzymes (Beermann, 1979). On the other
hand drugs absorbed by saturable mechanisms or from specific intestinal sites may
exhibit increased absorption due to a decrease in the rate at which the drug passes its
absorption site (Toothaker and Welling, 1980). In addition to changes in absorption
resulting from physiological effects, altered absorption may also result from direct
interactions between food components and drugs, generally resulting in decreased
bioavailability. Food may also act as a purely physical barrier preventing a drug from
reaching the gastrointestinal surface (Beermann, 1979).
As judged mainly from single meal, single dose studies in healthy volunteers, food has
been shown to increase the bioavailability of several antihypertensive drugs. Areas
under the plasma concentration time curves for propranolol, metoprolol and hydralazine
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were significantly larger when administered with food compared to the fasting state
(Melander et al. 1977a, b). There is evidence that the gastrointestinal absorption of
propranolol and metoprolol is virtually complete under fasting conditions (Shand,
1974), and it was therefore suggested that food intake somehow reduced their first pass
metabolism in the liver (Melander, 1977a, Melander and McLean, 1983). A similar
mechanism may explain the increased bioavailability of hydralazine (Melander, 1978).
The amount of hydrochlorothiazide recovered in the urine was also increased when
given with food (Beermann and Groschinsky-Grind, 1978). A possible explanation was
that food, by inhibiting stomach emptying, decreased tha rate at which the drug passed
its absorption site in the upper small intestine. Other drugs incuding diphenylhydantoin
(Melander et al. 1979a) and nitrofurantoin (Rosenberg and Bates, 1976) also show
increased absorption following administration with food. All orally administered drugs
must be in solution before they can be absorbed (Rowland and Tozer, 1980) and a
possible explanation put forward for both drugs was that delayed stomach emptying
allowed for more effective tablet disintegration and drug dissolution in the stomach
before they pass into the optimal absorption site of the small intestine (Bates, 1974;
Melander et al. 1979a). Griseofulvin absorption is increased by high fat meals but not by
high protein or carbohydrate meals in normal individuals (Welling, 1977b). This is most
probably explained by fat induced enhancement of the dissolution ofgriseofulvin, which
is extremely lipophilic (Bates et al. 1966).
In contrast, several antimicrobial agents have reduced bioavailability when administered
with food. The absorption of oxytetracycline and tetracycline is drastically reduced by
the intake of calcium rich foods such as milk and cheese due to chelates forming between
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the metals and the tetracyclines (Neuvonen and Turakka, 1974; Neuvonen 1976). Food
has also been reported to reduce the absorption of penicillinV, penicillin G,
penicillamine, ampicillin and oxacillin (McCarthy and Finland. 1960; Osman et al. 1982;
Welling, 1977b). On the other hand the bioavailability ofamoxycillin seems unaffected
by food (Melander, 1978). Peak plasma concentrations and areas under the plasma
concentration-time curve of isoniazid were also significantly decreased by food
(Melander et al. 1976) and delay in gastric emptying consequent to food was proposed
as the explanation although direct interaction of isoniazid and food components may
also be important (Melander et al. 1976). Other drugs whose bioavailability is reduced
by food include atenolol (Melander et al, 1979b), captopril (Singhvi et al. 1982) and
ketoconazole(Mannisto etal. 1982).
For drugs such as diazepam, digoxin and quinidine, the rate ofdrug absorption is delayed
but the total quantity of drug available to the systemic circulation is not reduced when
t
either drug is ingested with a meal (Greenblatt et al. 1974; Greenblatt et al. 1978;
Johnson et al. 1978; Woo and Greenblatt, 1980). Wessels et al (1992) showed that
breakfast with a high fat content delayed the absorption of paracetamol. Breakfast with
a high carbohydrate or cereal content influenced the rate of absorption to a lesser extent.
Food intake seemed to reduce the rate ofparacetamol absorption due to retarded gastric
emptying (Heading et al. 1973; McGilveray and Mattok, 1972; Nimmo et al. 1973,
1975).
Concomitant food intake appears to have no apparent influence on the absorption and
bioavailability of drugs such as oxprenolol (Dawes et al. 1979), bendroflumethaizide
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(Beennannc'/a/. 1978) and oxazepam (Melander e/ al. 1977 c).
The formulation in which a drug is administered also has a profound effect on the extent
ofa particular drug-food interaction. While the uptake of nitrofurantoin from tablets is
enhanced when administered with food, the absorption of the drug from a suspension is
unaffected (Rosenberg and Bates, 1976). The absorption of aspirin from conventional
tablets appears to be reduced by food (Spiers and Malone, 1967) but absorption from
effervescent tablets is only slight delayed (Volans, 1974). Finally, the uptake of two
esters of erythromycin is also decreased when given as a tablet with food (Hirsch and
Finland, 1959) however it remains unaffected when administered as a suspension
(Hirsch etal. 1960).
Food ingestion can therefore increase, decrease, delay or have no effect on drug
absorption. Also different food components may have different effects, different
preparations of the same drug may interact differently with food and foodmay interact in
opposite ways, even with drugs that are chemically related. Therefore, the net result of
food on drug bioavailability can only be derived from direct studies of the drug in
question.
Although studies in healthy subjects have previously been carried out to determine the
effects of food on oral frusemide absorption, the results have been variable. Some
suggested that its absorption may only be delayed by the intake of breakfast (Kelly et al.
1973;Hammarlundc7 a/. 1984), while another found that breakfast significantly reduced
its bioavailability to an extent where efficacy may be impaired (Beermann and Midskov,
1986). No definitive studies of the effects food on bumetanide absorption have been
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reported. In light of this information, the unpredictable nature of food on drug
bioavailability and the fact that many patients take medication at mealtimes, the effect of
food on frusemide and bumetanide absorption in man has been compared.
Because patients receiving medication may also receive more than one drug at a time,
interactions between drugs represents another major problem in drug therapy. Since the
sites of frusemide action are primarily reached via the organic acid secretory pump at the
proximal tubule (Andreasen et al. 1978; Calesnick et al. 1966; Odlind, 1979), the
presence of other coadministered acids may interfere with its transport into the tubular
lumen. It was therefore decided, in another study, to detemine the effects of intravenous
penicillin , another commonly used drug also secreted via the proximal tubules, on the
renal elimination and response of frusemide. This potential drug-drug interaction has
not previously been investigated. As mentioned earlier, numerous studies in animals and
man (Brater, 1978; Chennavasin el al. 1979; Friedman and Roch-Ramel, 1977;
Homeida et al. 1977; Honari et al. 1977; Hook and Williamson, 1965; Odlind,1979;
Sommers et al. 1991) have previously shown that probenecid pretreatment significantly
reduces the renal clearance offrusemide (up to 78 % in the study by Homeida et al. 1977)
by competing for renal secretion.
An unexpected finding from some of these studies (Brater, 1978; Chennavasin et al.
1979; Sommers et al. 1991) however was that pretreatment of healthy subjects with
probenecid increased the overall natriuretic response to frusemide. Since the dose
response curves were found to be identical, the effect did not occur because of changed
sensitivity ofthe nephron to frusemide (Brater, 1978).
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A similar phenomenon has been found in studies comparing overall response to oral and
intravenous frusemide (Branch, 1977; Kaojarern et al. 1982; Kelly et al. 1973). Branch
et al (1977) found that the natriuretic response by either route was virtually the same,
despite approximately half as much frusemide reaching the site of action with the oral
dose compared to the intravenous dose. Kelly et al {1973) also compared the response
between different formulations and routes of administration of frusemide in healthy
volunteers. They again found no significant differences in total sodium excretion after
oral versus intravenous administration, while the oral bioavailability of drug was
approximately half that after intravenous administration. As with the probenecid effect
there was a discrepancy between overall response relative to the amount of drug
reaching the active site.
Kaojarern et al (1982) suggested that in addition to frusemide absorption and the total
amount of drug in the urine, the time course of delivery of frusemide into the urine was
another independent determinant of overall response. They calculated a maximally
efficient excretion rate for frusemide and found that amounts of frusemide after an oral
dose more persistently approached the amount with maximal efficiency compared to an
intravenous dose. In accordance with this concept several investigations in healthy
volunteers found that intravenous infusion of frusemide led to a better response than
bolus injection (Lahav etal. 1992;Meyelc7a/. 1992).
Ifsmall repeated oral doses of frusemide were given at regular intervals, steady levels of
the drug may be obtained which may also result in greater cumulative sodium excretion.
Consequently, a slow release oral preparation of frusemide may be a more efficient way
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to administer such a drug. This hypothesis was tested by comparing the
pharmacokinetic and dynamic effects of a single oral dose of frusemide with an
equivalent dose administered at hourly intervals in healthy subjects.
The information obtained from the following studies may lead to the more effective use
of frusemide and bumetanide in clinical practice, in particular, by controlling the times of
administration in relation to meals.
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Aims
The following studies were undertaken to:
1) Determine the effects offood on frusemide absorption in healthy volunteers
2) Determine the effect offood on bumetanide absorption in healthy volunteers
3) Obtain information on the general use of frusemide and bumetanide in two medical
wards within the Edinburgh Royal Infirmary
4) Establish the effect ofhospital breakfast on the absorption and efficacy of frusemide in
hospital patients
5) Determine whether frusemide absorption was dose-dependent
6) Study the effects ofpenicillin on frusemide renal secretion and diuretic effect
7) Compare the pharmacokinetic and pharmacodynamic effects ofthe same total dose of




Section 2.1: Analytical Methods
Measurement of frusemide in plasma and urine by high performance liquid
chromatography
Background
Over the years many methods have been developed for the analysis of frusemide in
biological samples. The earliest were based on spectrophotometry (Haussler and Hadju,
1964), others employed gas chromatography (Lindstrom and Molander, 1974) and thin
layer chromatography (Steiness et ah 1979; Yakatan et ah 1976). Subsequently, in
order to improve sensitivity, several high performance liquid chromatography methods
were developed (Andreasen et al. 1981; Carr etal. 1978; Kerremans etal. 1982; Lin et
al. 1979; Nation et al. 1979; Rapaka etal. 1982; Sood etal. 1987; Uchino etal. 1984).
The reason for such extensive literature regarding the analysis of frusemide relates to
problems associated with its stability.
Several methods used liquid-liquid extraction before chromatography ( Andreasen etal.
1981; Carr et al. 1978; Lindstrom, 1974; Perez et al. 1979; Steiness et al. 1979).
Typically, samples were acidified with hydrochloric acid before extraction with ether.
The organic phase was then evaporated and the residue dissolved in a suitable solvent for
injection. Acidification ofthe samples was necessary to separate frusemide from plasma
protein and transfer it to the organic layer. However, under acidic conditions
degradation of frusemide occurs with the formation of 4-chloro-5-
sulphamoylanthranilic acid (CSA)(Cruz et al. 1979; Kovar et ah 1974; Rowbotham et
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al. 1976), complete transformation being achieved by heating an acid solution of
frusemide to 70° for 45 minutes (Fig 2.1) (Hadju & Haussler, 1964). Using 1.5M
hydrochloric acid as acidifying agent Kerreman et al (1982) obtained a recovery of
frusemide of 50 % because of degradation. However no degradation of frusemide was
observed using acetic acid as the acidifying agent. Also Smith etal (1980) using a urine
sample known to contain frusemide but no CSA were able to detect a CSA peak after
applying the acid extraction procedure described by Perez etal( 1979). Using their own
direct injection method, no CSA was detected in any of the samples analysed. This
degradation of frusemide may be even faster if sulphate ions are present as in human
urine (Shah etal. 1980).
This problem is further complicated by the fact that the fluorescence of frusemide is
optimal at low pH. Using frusemide made up in phosphate buffers ofvarying pH, Blair et
al{\ 975) discovered that the relative fluorescent intensities for frusemide were 100 % at
pH 1.6, 97 % at pH 2.5 and 81 % at pH 4.6. At pH 5.6 and 6.6 frusemide did not
fluoresce. However, despite the necessity to bring samples into an acid pH range,
fluorescence detection offers much greater sensitivity and has been favoured by several
investigators (Kerremanst?/ al. 1982;Lovett etal. 1985;Rapaka(?fa/. 1982; Smith a/.
1980).
The stability of frusemide to light has also been questioned (Moore and Sithipitaks,
1983). Several methods have recommended exclusion of light from biological samples
(Sood etal. 1987; Steiness et al. 1979; Uchino etal. 1984), mostly without any further
explanation. However Kerreman et al {1982) demonstrated that fast degradation took
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Figure 2.1. Frusemide (4 chloro-N-furfuryl-5-sulfamoylanthranilic acid). The dashed
line indicates the degradation resulting from exposure to heat and acid. The split product
CSA is left ofthe dotted line
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place when solutions of frusemide in phosphate buffers of varying pH were exposed to
light. Similar results were obtained with frusemide in human urine. When the same
samples were protected from light 100 % recovery of frusemide was obtained. On the
other hand Lovett et al (1985) found it unnecessary to protect their samples from light
during sample extraction. Frusemide stability was tested in each of the solvents used in
the assay and no photolytic degradation was observed.
The studies above outline the degradation problems in handling frusemide but also
suggest that they may be prevented by taking appropriate precautions. The analytical
method described below avoids the use ofstrong acids and light has been excluded from
samples where possible.
Method
Frusemide concentrations in plasma and urine were measured by High Performance
Liquid Chromatography (HPLC) with fluorescence detection. The components of the
HPLC system used are shown in Fig. 2.2.
Measurement offrusemide in plasma
Frusemide was extracted from plasma using a solid phase extraction technique
developed byRussel et al. (1989). The extraction is based on the selective adsorption of
frusemide onto covalently bonded silica (C "Bond Elut") columns (see Fig 2.3).18
Samples are drawn through the columns using a vacuum system ("Vac Elut SPS 24").
Components of the Vac Elut system are given in Fig. 2.4.
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Figure 2.2. High performance liquid chromatography system used for the measurement
offrusemide in plasma and urine
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A) Sample containing isolate ■ and interferences ® 0's Passet^ through sorbent
B) Sorbent selectively retains isolate
Other interferences pass unretained
and some interferences
C) Sorbent is washed with appropriate solvent to elute retained interferences









Figure 2.3. Diagram explaining the stages of solid phase extraction
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Figure 2.4. Components of the "Vac Elut" system used during solid phase extraction.
The system accepts up to 24 Bond Elut columns.
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Materials
Desmethylnaproxen, the internal standard, was kindly supplied by Syntex (Riccarton,
Edinburgh). Potassium dihydrogen orthophosphate, citric acid, orthophosphoric acid,
potassium hydroxide and urea were all supplied by BDH Chemicals Limited (Poole,
England). Methanol was HPLC grade. "Bond Elut" columns were manufactured by
Varian (Harbor City, USA) and supplied by Jones Chromatography (Mid-Glamorgan,
Wales).
Plasma Standards
Stock solutions (1 g/1) of frusemide and desmethylnaproxen (DMN) in methanol were
prepared in amber standard flasks. Standard solutions of frusemide were prepared by
dilution of the stock using drug free plasma. Two standard ranges were used,
0.05 - 0.5 mg/1 and 0.05-2 mg/1. A blank plasma standard was included in each range.
100 pi of 2 mg/1 and 100 pi of 10 mg/1 DMN were used as the internal standards. All
standards were protected from light by wrapping aluminium foil around the containers
and were stored in a freezer at approximately -20°C.
SamplePretreatment
Prior to analysis all standards and unknowns were pretreated as follows. 100 pi ofDMN
were pipetted into 10 ml amber test tubes. The DMN was evaporated to dryness under a
stream of nitrogen at room temperature. Aliquots of 0.5 ml of plasma and 1.5 ml of a
50% (w/w) aqueous solution of urea were successively pipetted into each tube. The
tubes were vortex mixed for 1 second and allowed to stand for 10 minutes. Urea
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denatures the protein in plasma to which frusemide is extensively bound (>95%)
(Andreasen el al. 1974; Forrey et al. 1974; Smith et al. 1980). 2 ml of a 0.01 M
potassium citrate buffer (pH 3.0) were then added to the tubes. Finally the tubes were
vortex mixed for 1 s. The samples were then ready to be loaded onto the "Bond Elut"
solid phase extraction columns.
NonpolarSorbentExtraction
Compounds with non polar functional groups can be extracted from polar solutions
using a non polar sorbent. The sorbent used was non-polar C octadecyl silica (ODS).18
Prior to use the "Bond Elut" columns were solvated which creates an environment
suitable for isolate retention. This was accomplished by drawing 3 ml of methanol
followed by approximately 3 ml of 0.01 M potassium citrate buffer (pH 5.0) through
each column. The prepared plasma samples were then loaded onto the columns and
drawn through. The columns were washed with 10 ml of the same pH 5.0 buffer.
Frusemide and DMN were eluted from the sorbent using 1 ml of a 50:50 mixture
consisting of 0.01 M aqueous sodium hydrogen carbonate and methanol (pH 9.2). The
eluates collected were ready for HPLC analysis.
Apparatus andChromatographic Conditions
The HPLC system consisted of a Waters 510 HPLC pump which delivered the mobile
phase to an automatic sample injection module, theWaters Intelligent Sample Processor
(710B). Separation was carried out using a Radial Compression reverse phase column
( Nova Pak C ODS, 4pm). The column was kept at a constant temperature of 40°C18
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using a Waters chromatography oven and was protected with both a metal filter and a
precolumn packed withNova-Pak C Both frusemideand DMN weremeasured with a
Perkin Elmer Luminescence Spectrophotometer. The excitation wavelength was set at
275 nm and the emission wavelength at 400 nm. The signal from the spectrophotometer
was detected by a DCS computer running a JCL6000 Chromatography Data System
which provided full analysis of the chromatograms. The mobile phase consisted of
methanol and 0.02 M phosphate buffer pH 3.0 (48:52). It was degassed with helium
before use and was delivered at a constant rate of 1 ml/min.
RelativeRecovery
The recovery of frusemide was determined as follows. 0.5 and 2 mg/1 frusemide
solutions were prepared in methanol. 0.5 ml of each solution was mixed with 100 pi of
10 mg/1 DMN and evaporated to dryness under a stream of nitrogen at room
temperature. The residues were then reconstituted in 1 ml of the 50:50 mixture of
methanol and sodium hydrogen carbonate and injected into the HPLC system. Plasma
samples also containing 0.5 and 2 mg/1 frusemide were extracted as previously described
and then injected onto the column. Recovery with the extraction procedure was
determined by comparing the peak height ratio (frusemide/DMN) obtained after
injection of extracted plasma with the peak height ratio obtained after injection of non-
extracted solutions of frusemide in methanol
StabilityStudy
Stability studies were performed on plasma samples containing 0.5 and 2 mg/1
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frusemide. The samples were either left on the bench, refrigerated at 4°C or frozen at




The total run time for each sample was 6 minutes in which frusemide and DMN were
eluted from the column with retention times of approximately 3.3 and 4.4 minutes
respectively. Fig 2.5 shows typical chromatograms obtained for drug free plasma and
for plasma containing 0.2 and 1.2 mg/1 frusemide.
Standard Curves
For each standard a peak area ratio was calculated by dividing the area of the frusemide
peak by the area ofthe DMN peak. Plots were drawn ofpeak area ratio versus frusemide
plasma concentration. The relationship was linear over the frusemide concentration
range 0.05-1 mg/1 (r= 0.9991, n=5) and 1-10 mg/1 (r=0.9998, n=5). The 0.05-0.5 and
0.05-2 mg/1 ranges of plasma standards were assayed on five separate days. The results
are shown in Tables 2.1 and 2.2 and Figs 2.6 and 2.7. The coefficient ofvariation of the
assay, calculated from five replicate determinations was less than 10 % for both ranges.
A calibration plot was constructed each time a set ofunknown samples were analysed.
Relative Recoveries
The relative recoveries offrusemide after solid phase extraction are given in Table 2.3.
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Figure 2.5. Typical chromatograms resulting from the analysis of a plasma samples
collected from a healthy volunteer after receiving 40mg oral frusemide. The
chromatograms show a) drug free plasma b) plasma sample containing 0.2 mg/1




Table 2.1. Variation in plasma frusemide assay for 0.05 - 0.5 mg/1 during 6 standard












1 2 3 4 5 6
0.05 0.24 0.23 0.24 0.20 0.19 0.19 0.22 ±
0.02
9.09
0.1 0.36 0.38 0.42 0.38 0.39 0.38 0.39 ±
0.02
5.13
0.2 0.66 0.72 0.72 0.68 0.70 0.70 0.70 ±
0.02
2.86
0.4 1.46 1.49 1.44 1.36 1.41 1.44 1.43 ±
0.04
2.80




Table 2.2. Variation in plasma frusemide assay for 0.05 - 2 mg/1 during 5 standard












1 2 3 4 5
0.05 0.06 0.07 0.06 0.05 0.06 0.06 ±
0.006
10.00
0.1 0.11 0.10 0.10 0.10 0.10 0.10±
0.004
4.00
0.5 0.48 0.46 0.51 0.47 0.45 0.47 ±
0.02
4.26
1 1.00 0.95 1.00 1.00 0.92 0.97 ±
0.03
3.09




Peak area ratio (F/DMN)
Plasma frusemide cone (mg/l)
Figure 2.6. Mean standard curve obtained for 0.05 - 0.5 mg/l frusemide in plasma
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peak area ratio (F/DMIM)
Plasma frusemide cone (m g/1)
Figure 2.7. Mean standard curve obtained for 0.05 - 2 mg/1 frusemide in plasma
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Table 2.3. Relative recovery of frusemide from plasma after solid phase extraction.
Values were obtained by comparing peak height ratios obtained after injection of
extracted plasma samples containing frusemide with peak height ratios obtained after
injection of non-extracted solutions of frusemide in methanol. For all concentrations,








When the plasma samples were left on the bench frusemide remained stable for up to
24 h. After this time a gradual reduction in peak height ratio occurred with the
appearance of an additional peak running at 2.2 minutes on the chromatogram. This
peak increased in size over the next few weeks. No such peak was present in the samples
kept in the fridge or freezer. No instability was detected for up to 1 week in refrigerated
samples and up to 8 weeks in frozen samples.
Measurement offrusemide in urine
Urine samples were injected directly into the HPLC system. No extraction procedure
was thought necessary as there was no interference from endogenous peaks. 200 pi of
each urine sample were pipetted into tubes together with 150 pi of 2 mg/1 DMN. The
tubes were whirlimixed before analysis. All apparatus and chromatographic conditions
were the same as for frusemide in plasma except that the oven was set to 30° C. This
provided better peak separation between frusemide and DMN in the urine.
Urine Standards
*
For estimating the concentration of frusemide in urine samples, standard solutions were
made up with final concentrations ranging from 0.1- 5 mg/1. 150 pi of2 mg/1 DMN was
used as the internal standard. 200 pi volumes of each urine standard were frozen in
individual test tubes. This was the amount used during analysis. This not only reduced
the time of analysis but also eliminated the repeated thaw and freeze shock to the
standards. It has previously been shown that standards stored in individual containers
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remain stable for longer compared with those stored in larger containers and repeatedly
exposed to thaw and freeze cycles (Sood et al. 1987).
StabilityStudy
Stability studies were also performed on urine samples containing 0.1, 1 and 5 mg/1
frusemide. Again samples were either left on the bench, refrigerated or frozen.
Results
Chromatograms
Chromatograms for drug free urine and for urine containing 2.5 mg/1 frusemide are
shown in Fig. 2.8. The total run time for each urine sample was 6 minutes in which
frusemide and DMN were resolved with retention times of 3.4 and 4.8 minutes
respectively.
StandardCurves
Urine standard curves were linear over the range 0.1-1 mg/1 (r = 0.9989, n=5) and
1-10 mg/1 (r = 0.9998, n=5). The 0.1-5 mg/1 range offrusemide standards were assayed
on five separate days. The results are shown in Table 2.4 and Fig. 2.9. The coefficient of
variation ofthe assay for five replicate analyses was less than 6 %.
Stability
No instability was detected for up to 24 h in the urine samples left on the bench.
Subsequently a gradual decrease in peak height ratio was observed at each concentration
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Figure 2.8. Typical chromatograms resulting from the analysis of urine samples
collected from a healthy volunteer after receiving 40 mg oral frusemide. The
chromatograms show a) drug free urine b) urine sample containing 2.5 mg/1 frusemide
collected 1 - 2 h after drug administration.
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Table 2.4. Variation in urine frusemide assay for 0.1-5 mg/1 during 5 standard runs












1 2 3 4 5
0.1 0.10 0.10 0.10 0.09 0.10 0.10 ±
0.004
4.00
0.5 0.48 0.49 0.45 0.47 0.44 0.47 ±
0.02
4.26
1.0 0.91 0.94 0.86 0.86 0.88 0.89 ±
0.03
3.37
2.0 1.74 1.82 1.74 1.77 0.61 1.74 ±
0.07
4.02




Peak area ratio (F/DMN)
Urine frusemide cone (mg/l)
Figure 2.9. Mean standard curve obtained for 0.1-5 mg/l frusemide in urine
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After 4 weeks no frusemide peak could be detected in either the 0.1 or 1 mg/1 plasma
samples. In the refrigerated and frozen samples no instability was detected for up to 4 and
10 weeks, respectively.
Measurement of bumetanide in plasma and urine by high performance liquid
chromatography
Background
Gas chromatographic (Feit et al. 1973), radioactivity (Halladay et al. 1977),
radioimmune (Dixon etal. 1976) and high performance liquid chromatographic (Ameer
& Burlingame, 1988; Bokens. et al. 1988; .Marcantonio et al. 1980; Smith, 1982;
Walmsley et al. 1981) assays are available for the determination of bumetanide in
biological samples. Some of these methods have inherent disadvantages including long
extraction or incubation steps, relatively large sample sizes, lack of sensitivity and dual
detection for bumetanide and the internal standard. Unlike frusemide however, no
stability problems have been reported for bumetanide. Bumetanide is stable for up to 24 h
in plasma at acidic pH (Singh et al. 1989), up to 48 h in refrigerated samples and up to 6
weeks frozen (Wells etal. 1991).
Measurement of bumetanide in plasma
Concentrations ofbumetanide in plasma were analysed using solid phase extraction and
HPLC with fluorescence detection according to Wells et al (1991) with some
modifications. It provides a sensitive, simple and relatively quick analytical method.
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Materials
Bumetanide was kindly supplied by Leo Laboratories Limited (Aylesbury, England).
Disodium orthophosphate and dipotassium hydrogen orthophosphate were supplied by
BDH Chemicals Limited (Poole, England). Piretanide was used as the internal standard.
Plasma Standards
Stock solutions of bumetanide (0.5 mg/ml) and piretanide (1 mg/ml) were made up in
methanol in standard flasks. Standards were prepared by dilution of the bumetanide
stock solutions using drug free plasma. Two standard ranges were used, a low range
(2.5 - 100 pg/1) and a high range (50 -500 pg/1). Both ranges contained a blank plasma
standard. The corresponding internal standards used were 200 p 1 of2 mg/1 piretanide for
the low range and 100 pi of25 mg/1 for the high range.
SamplePretreatment
All standards and unknown samples were pretreated as follows. To each 0.2 ml ofplasma
the appropriate amount ofpiretanide was added. 0.4 ml ofacetonitrile was then added to
precipitate the proteins. Each sample was vortex mixed for approximately 30 seconds
and centrifuged at 2000 rpm for 10 minutes. The supernatant was transferred to a 10 ml
test tube and 4 ml ofa 0.1 M phosphate buffer (pH5.0) was added. Bumetanide was then
isolated using solid phase extraction.
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NonpolarSorbentExtraction
Cjs ODS "Bond Elut" columns were used. Prior to introducing the plasma samples, the
columns were washed sequentially with 0.6 ml ofacetonitrile, 2 ml ofmethanol and 3 ml
ofdeionised water. The samples were then loaded onto the columns. The columns were
washed with 3 ml of water. Bumetanide and piretanide were eluted with 0.3 ml of
acetonitrile. The eluates were placed in a water bath at 37°C and evaporated to dryness
under a stream ofnitrogen. They were then reconstituted in 0.2 ml of the HPLC solvent
and injected.
Apparatus andChromatographic conditions
The same apparatus was used as described for the frusemide assay. The samples were
analysed at room temperature. The luminescence spectrophotometer was set at
excitation wavelength 228 nm and emission wavelength 418 nm. A Waters 5 pm
"Resolve" C column was used. It was protected with a precolumn of the same
packing. The mobile phase consisted of methanol, deionised water and acetic acid
(66:34:1 v/v) and was delivered at a flow rate of 1.2ml/minute.
RelativeRecovery
Recovery experiments were conducted using known concentrations of bumetanide in
methanol and plasma. Bumetanide in methanol (10 and 100 pg/1) was evaporated to
dryness and reconstituted with 200 pi of the HPLC eluent. Piretanide was added and an
aliquot injected onto the column. Plasma samples also containing 10 and 100 pg/1
bumetanide were prepared and extracted as previously described. Recoveries of
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bumetanide from plasma after solid phase extraction were determined by comparison of
peak height ratios obtained from plasma with those of non-extracted solutions of
bumetanide in methanol.
Stability
Stability studies were performed on refrigerated (4° C) and frozen (-20°C) aliquots of
plasma containing 20 pg/1 bumetanide. Several aliquots were also left on the bench.
Results
Chromatograms
Bumetanide and piretanide in plasma were monitored over a total run time of 8 minutes
and were eluted from the column with retention times of 6.5 and 5.1 minutes
respectively. Fig 2.10 shows chromatograms obtained from blank plasma and plasma
containing 11.7 and 99.6 pg/1 bumetanide.
StandardCurves
The 2.5-100 pg/1 and 50 - 500 pg/1 bumetanide plasma standard ranges were assayed on
five separate occasions. The results are shown in Tables 2.5 and 2.6 and Figs 2.11 and
2.12. The coefficient of variation of the assay was less than 10 % for the low range and
less than 6% for the high range.
Recovery


















Figure 2.10. Typical chromatograms resulting from the analysis of plasma samples
collected from a healthy volunteer after receiving 2 mg bumetanide. The
chromatograms show a) drug free plasma b) plasma sample containing 11.7 pg/1
bumetanide and the internal standard, piretanide c) plasma sample containing 99.6 pg/1
bumetanide and piretanide.
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Table 2.5. Variation in plasma bumetanide assay for 2.5 - 100 pg/1 during 5 standard












1 2 3 4 5
2.5 0.09 0.10 0.09 0.11 0.09 0.10±
0.008
8.00
5 0.17 0.18 0.16 0.18 0.17 0.17 ±
0.01
5.88
10 0.32 0.31 0.30 0.36 0.32 0.32 ±
0.02
6.25
20 0.62 0.63 0.57 0.69 0.68 0.64 ±
0.04
6.25
50 1.45 1.45 1.39 1.55 1.55 1.48 ±
0.06
4.05
100 2.94 2.84 2.76 3.11 2.78 2.89 ±
0.13
4.50
Table 2.6. Variation in plasma bumetanide assay for 50 - 500 pg/1 during 5 standard












1 2 3 4 5
50 0.26 0.25 0.28 0.28 0.28 0.27 ±
0.01
3.70
100 0.52 0.47 0.50 0.52 0.49 0.50 ±
0.02
4.00
250 1.32 1.17 1.24 1.24 1.17 1.23 ±
0.06
4.88




Peak area ratio (bumetanide/piretanide)
Plasma bumetanide cone (jjg/l)
Figure 2. 11. Mean standard curve obtained for 2.5-100 pg/1 bumetanide in plasma.
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Peak area ratio (bumetanide/piretanide)
Plasma bumetanide cone (/jg/l)
Figure 2.12. Mean standard curve obtained for 50 - 500 pg/1 bumetanide in plasma.
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Table 2.7. Relative recovery of bumetanide from plasma after solid phase extraction.
Values were obtained by comparing peak height ratios obtained after injection of
extracted plasma samples containing bumetanide with peak height ratios obtained after
injection of non-extracted solutions ofbumetanide in methanol. For all concentrations,







are given in Table 2.7.
Stability
No instability was detected for up to 72 h in the plasma samples left on the bench. A
reduction in peak height ratio then occurred and after 3 weeks no peak for bumetanide
could be detected. The refrigerated and frozen samples were stable for at least 12 weeks.
Measurement ofbumetanide in urine
Urine samples were introduced directly into the HPLC system. 200 pi of each urine
sample were pipetted into tubes together with 200 pi of 10 mg /I piretanide. The tubes
were whirlimixed before analysis. The chromatographic conditions were the same as for
the plasma samples.
UrineStandards
Standard solutions of bumetanide in urine were made up with final concentrations
ranging from 0.1 - 1 mg/1. The internal standard used was 200 pi of 10 mg/1 piretanide.
Stability
Similar stability studies were performed on refrigerated and frozen aliquots of urine




The total run time for each urine sample was 9 minutes. Bumetanide and piretanide were
eluted with retention times of 6.6 and 5.2 minutes respectively. Chromatograms
obtained for blank urine and urine containing 0.3 mg/1 bumetanide are shown inFig2.13.
StandardCurves
The 0.1-1 mg/1 range of bumetanide urine standards were assayed on five separate
occasions, the results of which are given in Table 2.8 and Fig 2.14. The coefficient of
variation for the assay was less than 6 % for five replicate standard runs.
Stability
No instability was detected for up to 12 weeks in either the refrigerated or frozen
samples
Measurement ofurinary sodium and potassium concentrations
Sodium and potassium concentrations in urine were measured using ion specific
electrodes (KNA1 Na/K Analyser, Radiometer, Copenhagen).
Measurement ofplasma renin activity (PRA)
PRA was measured by radioimmunoassay of the decapeptide, angiotensin I. The assay
was based on the original method developed by Haber etal. 1969.
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Figure 2.13. Typical chromatograms resulting from the analysis of a urine sample
collected from a healthy volunteer after receiving 2mg oral bumetanide. The
chromatograms show a) drug free urine b) urine sample containing 0.35 mg/1
bumetanide collected 3 - 4 h after drug administration
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Table 2.8. Variation in urine bumetanide assay for 0.1-1.0 mg/1 during 5 standard












1 2 3 4 5
0.1 0.48 0.48 0.46 0.5 0.48 0.48 ±
0.01
2.08
0.2 0.90 0.89 0.94 0.84 0.90 0.89 ±
0.03
3.37
0.4 1.83 1.70 1.84 1.78 1.64 1.76 ±
0.08
4.54
0.6 2.67 2.65 2.8 2.55 2.64 2.66 ±
0.08
3.01
0.8 3.58 3.36 3.77 3.70 3.52 3.59 ±
0.14
3.90




Peak area ratio (bumetanide/piretanide)
Urine bumetanide cone (jjg/l)
Figure 2.14. Mean standard curve obtained for 0.1 - 1 mg/1 bumetanide in urine
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Generation ofangiotensin I
Plasma samples were thawed at room temperature. 200 pi of each plasma sample were
added to test tubes followed by 40 pi of phosphate buffer (pH 5.3) and 10 pi of an
inhibitor mix. The mix contained phenylmethylsulphonyl fluoride, dimercaprol and
8-hydroxyquinolone. These reagents inhibit the action of angiotensin converting
enzyme and angiotensinase. The tubes were mixed and incubated at 37°C for 1 h in a
shaking water bath. After exactly 1 h the tubes were removed to a tray of ice and 1 ml of
refrigerated deionised water added to arrest the reaction.
Radioimmunoassay ofangiotensin I
Each plasma sample was assayed in duplicate. To each tube the following were added,
100 pi of plasma sample from above, 400 pi of 0.5 % bovine serum albumin buffer
containing 0.1% lysozyme, 200 pi of angiotensin I antibody and 200 pi Iodine 125
angiotensin I label. Standard solutions containing known concentrations of
angiotensin I were also prepared in 0.25 % bovine serum albumin buffer. To allow
equilibration all tubes were incubated for 20-24 h at 4° . Free angiotensin I was then
separated by the addition ofdextran coated charcoal. Tubes were mixed and centrifuged
at 2000 rpm for 10 minutes at 4°. Supernates were decanted into identically labelled
tubes and radioactivity was counted using a 1275 Minigamma Counter (LKB, Wallac).
The counter automatically constructs a standard curve and results ofpaired test samples
are averaged and concentrations derived from the standard plot. Concentrations are
expressed as pmol ofangiotensin I generated h"11 ' ofplasma.
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Measurement ofaldosterone concentration in plasma
Aldosterone concentrations in plasma weremeasured using Coat-A-Count Aldosterone
solid phase radioimmunoassay kits (Diagnostic Products Corporation, Los Angeles).
The tubes in the kit are coated with antibody and aldosterone in the samples competes
with radiolabeled aldosterone for binding to antibody sites during an incubation step.
The tubes are decanted and counted. Sample concentrations are determined from a
standard curve.
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Section 2.2. Pharmacokinetic Analysis
Pharmacokinetics
Pharmacokinetics is the mathematical description of the time course of changes in the
concentration of drugs and their metabolites in the body. It deals primarily with drug
absorption, distribution and elimination. Various mathematical models have been
constructed to interpret such data (Rowland and Tozer, 1980; Gibaldi and Perrier,
1982).
One compartmentmodel
The most commonly employed approach to the pharmacokinetic characterisation of a
drug is to represent the body as a system of compartments. The simplest case is the one
compartment model whereby it is assumed that a drug is introduced into the circulation,
distributed instantaneously throughout the body and eliminated at a rate proportional to
its concentration. This is termed first order elimination and it is an exponential process
(Gibaldi and Perrier, 1982).
Two compartmentmode!
In practice, however, the one compartment model is usually inappropriate. Tissue
uptake and drug distribution both take time. In such a case, following a rapid
intravenous injection, two phases are seen on a log plasma concentration versus time
plot (See Fig. 2.15). Initially there is a rapid decline in plasma concentrations. This fall,
in addition to the process of elimination, represents drug distribution into peripheral
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Plasma drug concentration (mg/l)
Time (h)
Figure 2.15. Log plasma concentration versus time plot following rapid intravenous
drug administration. The early rapid decline in plasma concentrations represents the
processes ofdrug distribution and elimination. The slower phase represents elimination
only.
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tissues. When the process of distribution is complete, drug concentration falls more
slowly. This slower subsequent linear phase represents drug elimination only. In this
model the body is therefore considered as two separate but interconnected
compartments:
(a) a central compartment consisting of the circulation and well perfused organs into
which the drug distributes rapidly
(b) a peripheral compartment which represents the rest ofthe body where drug uptake is
slower (Gibaldi and Perrier, 1982)
Drug distribution and elimination therefore represent two simultaneously occurring
exponential processes. These 2 phases can however be separated graphically by
extrapolation and subtraction, a procedure known as the method of residuals or "curve
stripping" (See Fig. 2.16). The slope of the linear elimination phase (b) is extrapolated
back to zero time (B). The concentrations on this line are then subtracted from the actual
plasma concentration values at each time point. The residual values generated describe
the process of distribution with slope (a) and intercept A on the y-axis. The rate
constants (i.e. fractional rate of change in drug concentration in unit time) for the
distribution (k ) and elimination (k ) phases are given by 2.303a and 2.303b,d el
respectively. The curve stripping procedure can also be applied following oral and
intramuscular administration in order to separate out the process ofabsorption (See Fig.
2.17).
Certain other pharmacokinetic variables can be defined with the use of plasma
concentration time curves:
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Plasma drug concentration (mg/l)
Time (h)
Figure 2.16. By the method of residuals, the distribution and elimination processes can
be separated following intravenous administration of a drug. Elimination process has
slope 'b' and intercept B. Residual values (+) describe distribution process with slope 'a'
and intercept A..
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Plasma drug concentration (mg/l)
Time (h)
Figure 2.17 Following oral drug admnistration, the method of residuals can also be used
to separate out an exponential absorption process. The terminal elimination phase with
slope 'b' is extrapolated back to the y-axis. Subtraction of actual concentrations at each
time point from the extrapolated values gives a series of residual values with slope 'a'.




Maximum concentration achieved after drug administration
(2) Tmax
Time interval between drug administration and Cmax.
(3) Half-life or
Drug half-life is defined as the time taken for the plasma drug concentration, or the
amount ofdrug in the body to fall by one half. It is calculated from the terminal linear part
ofa log concentration versus time graph according to:
The elimination half-life is related to the rate constant (k () by the equation (Gibaldi and
Perrier, 1982):
tv = log 2 / slope (b) Equation 2.1
t = In 2 / k
'/2 el Equation 2.2
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(4) A rea under theplasma concentration time curve (A UC)
AUC can be estimated by the trapezoidal rule illustrated in Fig. 2.18 (Gibaldi and Perrier,
1982; Notari, 1987). If a perpendicular line is drawn from each concentration point
down to the x-axis, the areas produced are trapezoids. The area of each trapezoid is
given by the product ofthe average concentration and the time interval (t)
Area 1 = (C + C / 2) . t1 2 Equation 2.3.
The area from the last point to infinity is calculated by:
Area = C / k Equation 2.4.,
t-00 t el
where C = concentration at last time point, Kel = elimination rate constant.
Total AUC is therefore given by:
AUC = sum of individual areas + C / k
0-OO t Iel Equation 2.5
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Plasma drug concentration (mg/l)
Time (h)
Figure 2.18. Plot of plasma concentration-time data following intravenous drug
administration. Area 1, which is a trapezoid, can be calculated as a product of
(CI +C2/2) and t, the time interval. Summing all areaswill give the AUC.
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(5J Volume ofdistribution (Vd)
The apparent volume into which a drug distributes in the body at equilibrium is called the
volume of distribution. In a one compartment model it can be calculated by the
expression:
Vd = Dose / C Equation 2.6,
O
where Dose = actual dose ofdrug administered, C -theoretical plasma concentration at
o
time zero.
C is obtained by extrapolating the linear part of the log concentration time plot back to
O
the y-axis. However this is only true for a one compartment model with instantaneous
drug distribution and in other circumstances volume may be overestimated. A better
model independent way to determine Vd is to use the relationship:
Vd = Dose / Area, k Equation2.7,el
where Dose = fraction ofdose which reaches the circulation intact, Area = area under the
plasma concentration time curve, k = elimination rate constant.el
71
This expression, sometimes known as Vd can therefore be used to describe the
area
volume of distribution for drugs which follow multiexponential decay (Gibaldi and
Perrier, 1982; Rowland and Tozer, 1980).
(6) Clearance (CL)
Clearance ofa drug is defined as the volume ofblood from which all drug would appear
to be removed per unit time. Total body clearance is equal to the sum of all individual
clearances which comprise drug elimination and following parenteral administration is
given by:
CL = Intravenous Dose / AUC Equation 2.8.
0-OO 1
Total clearance can be divided into renal (CL ) and non renal (CL„„ ) clearances BvR7 NR7 J
adapting the above definition renal clearance can be defined as the fraction of the
apparent volume ofdistribution from which a drug is removed by renal excretion per unit
time. It can be estimated by:
CL = Amount excreted in timet / AUC Equation 2.9.R 0-t
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Non renal clearance is the difference between total and renal clearance.
(7)Bioavailability (F)
This is defined as the extent and rate of entry of an administered drug into the systemic
circulation intact (Rowland and Tozer, 1980). It can be determined either from:
F=AUC (extravascular) / AUC (i.v.) Equation2.10,0-OO 0-CO
or
F = Ae (extravascular) / Ae (intravenous) Equation 2.11,
where Ae = total amount ofdrug excreted.
Calculation ofall the variables described above is facilitated by use ofcomputer software
designed specifically for the treatment ofpharmacokinetic data.
"Siphar"
"Siphar" (Centre d'Etudes et de Recherche en Statistiques et Informatique Medicales,
Creteil cedex- France) is an interactive computer program which allows different kinetic
models to be fitted to the same set of data. Experimental data from a study are first
entered into a database. Using a "peeling" algorithm the user can then display
graphically a semi-log plot of drug concentration versus time and decide visually the
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number of exponentials suitable to describe the data. A theoretical curve is then
superimposed onto the experimental data points. The peeling algorithm therefore
provides an initial estimate ofparameters for the chosen exponential model. In order to
minimise the difference between the theoretical curve and the observed data these
unrefined parameters can then be iteratively improved by using different weighting
2 2
factors(l, 1/y, 1/y"). 1/yand 1/y" give increasingly less weight to lower concentration of
drug where analytical precision is lowest.
Several criteria can be used to evaluate the goodness of fit of a model to experimental
data: (a) residuals (differences between calculated and observed concentrations).
These should be randomly distributed according to the particular model used; (b)
coefficient of variation of each parameter. If the coefficient of variation is greater than
20-30 %, the lack of accuracy can be considered too large. The model and/or the
computed algorithm must then be revised.
From the derived "best fit" model the program calculates elimination half life,
absorption, distribution and elimination rate constants and the AUC . Volume ofr
0-OO
distribution (Vd), total clearance (CL) and renal clearance (CL ) were calculated usingR
Equations 2.7, 2.8 and 2.9.
In the following studies frusemide and bumetanide were administered orally and by
intravenous infusion over 5 or 10 minutes. Resulting plasma concentration time curves
werefitted using "Siphar".
Plasma concentration time curves following oral frusemide and bumetanide
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administration were fitted to a one compartment model with 2 phases according to:
Ct = -Aea+Beel Equation 2.12
where C is the plasma concentration at time't', A and B are the intercepts on the y-axis
representing absorption and elimination, respectively and k and k are the absorption
a el
and elimination rate constants ofthe drug (Gibaldi and Perrier, 1982).
When the drugs were administered by intravenous infusion, the plasma concentration
time curves were best described by a two compartment model. The concentrations in
plasma as a function oftime't' were calculated by:
C =D( 1 -ekd") / k T + B( 1 -ekel") / k T Equation 2.13
where t < T (T = duration of the infusion) and
-k.t -k.(t-T) -k t -k .(t-T)
C = D( 1 -e d )e d /kT + B( 1 -e )e /k^T Equation2.14
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where t > T, D is the intercept on the y-axis representing distribution and kd is the rate
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EFFECTS OF FOOD ON THE BIOAVAILABILITY OF FRUSEMIDE
77
Section 3.1. Introduction
Frusemide is a weak acid which is absorbed incompletely from the gastrointestinal tract
and there have been reports of considerable intra and interindividual variability in its
bioavailability (Ponto and Schoenwald, 1990; Smith et al. 1980; Waller et al. 1982).
The extent of absorption has previously been shown to be inconsistently influenced by
the presence offood.
Preliminary experiments in nonfasted intact rats suggested that oral absorption of
frusemide with food in the stomach was slower but more complete than in the absence of
food (Chungi et al. 1979). These results have not been substantiated in man. Kelly et al
(1973) and Hammarlund et al (1984) did not find statistically significant differences in
the extent of absorption of frusemide when given with food compared with the fasting
state. Hammarlund etal (1984) did find that food intake significantly delayed absorption
by approximately 60 minutes. On the other hand Beermann and Midskov (1986) found a
30% decrease in bioavailability when frusemide was administered after breakfast. This
produced a corresponding reduction in the total diuretic effect.
The aim of this study was to obtain additional information about the individual variation
and the effects offood on frusemide absorption.
Section3.2. Methods
Subjects
Eight healthy male volunteers aged 21-38 years (28 ± 5 yr) and weighing 51 to 82 kg
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(70 ± 10 kg) took part in the study. They were healthy according to medical history,
clinical examination and haematological and biochemical tests. All volunteers were
informed of the nature of the study and each gave written informed consent. The study
was approved by the Lothian Health Board Healthy Volunteers Studies Ethics of
Medical Research Sub-Committee. The volunteers were asked to:
(1) avoid alcohol for 24 h before each study day
(2) avoid taking any other medication for 1 week prior to and throughout the study
(3) fast from 22.00 h the night before each study day
Procedure
An open randomised design was used. Each volunteer was studied on 3 separate
occasions at least one week apart. On each occasion they attended the clinical
investigation room at approximately 8 am. On arrival, an intravenous cannula (Venflon
2, 18G) was placed into a vein in each forearm , one for the administration of drug and
fluid and one for blood sampling. After emptying their bladders the volunteers then
received one of the following:
(1) Intravenous frusemide (constant infusion over 5 min.) -40 mg
(2) Oral frusemide solution - 40 mg (Lasix injection solution 1 Omg/ml)
(3) Oral frusemide solution after breakfast - 40 mg (Lasix injection solution 1 Omg/ml)
The oral doses of frusemide were taken in 100 ml of orange squash (Kia-Ora) and
washed down with 100 ml of water. The breakfast consisted of fruit juice (200 ml),
scrambled egg, cornflakes with milk and 2 slices of toast with butter and jam. Subjects
receiving the oral dose took it immediately after breakfast.
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The volunteers remained supine throughout the study and had nothing to eat or drink up
to 5 h after dosing. A light lunch was provided between 5 - 6 h. To compensate for fluid
loss, 500 ml of0.9 % sodium chloride solution was administered intravenously over the
first hour using an "IMED 960" volumetric infusion pump. For the remainder of the
study hourly urine volumes were replaced by similar volumes of 5 % dextrose, again
given intravenously.
Venous blood samples (10 ml) were taken just before dosing and at 3, 5, 10, 15, 30, 45,
60, 90, 120 min. and hourly for the next 6 h after administration ofthe intravenous dose.
After the oral dose samples were taken at 0, 10, 15,30,45, 60, 75, 90, 105,120, 150, 180
min. and hourly for the next 5 h. All blood samples were collected in lithium heparin
tubes and centrifuged at 3000 rpm for 15 min. Plasma was stored at approximately
-20°C.
Urine was collected at 1, 2, 3, 4, 5, 6 and 8 h after dosing. The volunteers also completed
an 8- 24 h urine collection at home. Urine volumes were recorded and aliquots stored at
-20°C until analysis.
Analysis ofsamples
Concentrations of frusemide in plasma and urine were measured by high performance
liquid chromatography with fluorescence detection as described in Chapter 2. Urinary




Plasma concentration time curves after intravenous administration of frusemide were
fitted to the biexponential Equation 2.14, using the "Siphar" curve fitting and modelling
program.
Oral Dose
Following oral administration of frusemide in the fasting state plasma concentration time
curves were fitted to a one compartment model with 2 phases according to Equation
2.12. Plasma concentration time curves following oral administration with food could
not be fitted to the model by computer because of irregular absorption. The AUC ^ gh for
these data were calculated using the trapezoidal rule. The area beyond the last measured
concentration to infinity was estimated from the elimination rate constant obtained after
intravenous administration according to:
AUC = C /K ,
t-oo t el
where C is the last measured concentration-time point and K is the intravenous
t el
elimination rate constant. It was assumed that the disposition kinetics ofthe drug did not
change beyond this point.
The potential error in this estimation is quite small inasmuch as the extrapolated AUC
values represent only 1.6 - 8.1 % (4.6 ±2.4%) ofthe total AUC values.
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Statistics
All data are expressed as means ± standard deviations (s.d). Statistical differences




The mean plasma concentration versus time plot is shown in Fig 3.1 and the resulting
pharmacokinetic parameters in Table 3 .1. The mean biological half life calculated from
the terminal elimination phase was 96 ± 40 min.
The total plasma clearance (CL) offrusemide was 147.7 ± 28.3 ml/min. Of this the renal
clearance (CL ) was 99.1 ± 17.9 ml/min and the non renal clearance (CL ) was 48.6 ±v R' v nr
12.7 ml/min (See Table 3.2). Renal elimination therefore contributed approximately
67% to the overall elimination of frusemide. The volume ofdistribution was found to be
0.27±0. lOL/kg.
The amount offrusemide excreted unchanged in the urine over 24 h was 26.9 ± 1.38 mg,
which corresponds to 67.2± 3.4 %ofthedose.
Oral administration
Mean plasma concentration time curves for oral doses given with and without food are
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Time (h)
Figure 3.1. Mean plasma concentrations following intravenous administration of40mg
frusemide over 5 minutes to 8 healthy volunteers. Bars = ±s.d.
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Table 3.1. Pharmacokinetic data of frusemide 40mg given intravenously (mean ± s. d.)
Intercept/ Parameter Half-life
Constant estimate ±s.d. (min)
D (mg/1) 6.79±0.86
17 ± 7.5














































































































Figure 3.2. Mean plasma concentrations following oral administration of 40mg




Figure 3.3. Individual plasma concentration versus time curves following oral









The presence of food changed the shapes of the curves for all individuals. The mean
peak plasma concentration was reduced from 2.35 ± 0.49 to 0.51 ± 0.19 mg/1 (PO.OOl)
and the time to peak concentration was significantly delayed (0.69 ± 0.21 to
1.91 ± 0.93 h, P<0.01). The AUC averaged 3.54± 0.82 mg.h/1 when frusemide was0-OO ^
administered in the fasting state compared with 1.95 ± 0.72 mg.h/1 when administered
with food (Table 3.3). The difference was significant, P<0.01.
Bioavailability
Oral bioavailabilities of frusemide administered with and without food were calculated
according to Equation 2.10 and the results are given in Table 3.4. Bioavailability was
significantly reduced from 75.6 ± 10.6 % fasting to 43.2 ± 16.8 % when administered
with food (P<0.01).
Renal elimination
The urinary recoveries of frusemide following oral and intravenous administration are
shown in Fig 3 .4. In the first 2 h, urinary recovery of the drug was significantly higher
after the intravenous dose compared with both the oral doses. In the same period
frusemide recovery was also significantly higher on comparing the oral fasting dose to
the oral dose given with food. From 2-8 h however, urinary recovery of frusemide was
significantly higher for the oral dose administered with food. The mean 24 h recoveries
for each dose are shown in Fig 3.5. A significant decrease in the amount of frusemide
eliminated in the urine can be seen on comparing fasting (45.4 ± 7.9 %) and non-fasting
(29.6 ± 6.1 %) states. Both recoveries were significantly lower than the intravenous
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Table 3.4. Bioavailability of40mg oral frusemide administered with and without





Without food With food
1 5.40 80.2 37.0
2 4.54 87.7 75.6
3 3.21 60.1 45.8
4 4.02 66.9 58.7
5 4.48 85.0 27.2
6 5.52 75.7 22.8
7 4.99 61.9 49.5
8 4.96 87.3 28.6
Mean 4.64 75.6 43.2

















Figure 3.4. Urinary recoveries of frusemide 40mg following intravenous and oral
doses with and without food in 8 healthy volunteers. *P<0.001, compared to oral fasting
and oral with food: **P<0.001, compared to oral with food: ***P<0.05, compared to




Figure 3.5. Total urinary recovery of frusemide over 24h (% of administered dose)
following 40mg intravenous and oral doses with and without food in 8 healthy
volunteers. *P<0.001, compared to oral fasting and oral with food: **P<0.001,
compared to oral with food.
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dose (67.2 ±3.4%).
The bioavailability of fruseinide was also calculated from urinary recovery data
according to Equation 2.11. Using this method the bioavailability of frusemide
administered in the fasting state and with food were 67.4 ± 14.4 and 44.2 ± 10.3 %,
respectively. These values are not significantly different from the values calculated
using the areas under the plasma concentration-time curves.
The renal clearance of frusemide was not significantly lower for any of the oral doses
compared to the intravenous dose (See Table 3.2). Food therefore had no obvious
influence on the renal clearance of frusemide.
Sodium excretion
The urinary excretion of sodium, potassium and water following the administration of
frusemide are only presented for the first 8 h of the study because after this time the
volunteers went home and fluid intake was not standardised.
Mean sodium excretion rates and total urinary sodium excretion following intravenous
and oral administration of frusemide are given in Figs 3.6 and 3.7. No significant
difference in total sodium output over 8 h was found. However differences in patterns of
response were observed. Over the first 2 hours sodium excretion was significantly
higher for the intravenous dose compared to the oral dose given with food. No
significant difference was found between the intravenous and oral fasting dose.
Subsequently the rate of sodium excretion declined for both the intravenous and oral
fasting dose. From 2 h onwards, sodium excretion rates following the oral
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administration of frusemide with food were significantly higher compared with both the
intravenous and the oral fasting dose.
Potassium excretion
Mean potassium excretion rates and total potassium output following intravenous and
oral administration of frusemide are shown in Figs 3.8 and 3.9. Different patterns of
response were again obtained for the three dosage regimes. The intravenous dose
produced significantly higher potassium output over the first 2 hours compared to the
oral doses. However, over the latter part of the study a delayed response was obtained
for the oral dose given with food, producing significantly higher potassium excretion
from 2 - 8 h. Total potassium output over 8 h was found to be significantly higher for the
intravenous dose and the oral dose givenwith food compared to the oral fasting dose.
Urine volumes
A similar pattern of response was again observed for mean urinary volumes following
intravenous and oral administration of frusemide (Fig 3.10).The intravenous and oral
fasting dose produced significantly higher urinary volumes over the first 2 h but from
2-6 h urinary volumes were significantly higher following the oral dose administered
with food. Total urine output (See Fig 3.11) for all three doses, over 8 h, was found not
to be significantly different.
SideEffects
Subjects 5 and 7 experienced mild transient leg cramp 2 - 3 h after the administration of
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Sodium excretion rate (mmol/min)
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Time (h)
Figure 3.6. Mean sodium excretion rates induced by 40mg intravenous and oral
frusemide with and without food in 8 healthy volunteers. *P<0.0l, compared to oral




Figure 3.7. Total sodium output over 8h following 40mg intravenous and oral
frusemide with and without food in 8 healthy volunteers. No significant differences were
found.
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Time (h)
Figure 3.8. Mean potassium excretion rates induced by 40mg intravenous and oral
frusemide with and without food in 8 healthy volunteers. *P<0.05, compared to oral
fasting and oral with food: **P<0.001, compared to i.v. and oral fasting: ***P<0.05,
compared to oral fasting.
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Potassium output (mmol)
Figure 3.9. Total potassium output over 8h following 40mg intravenous and oral
frusemide in 8 healthy volunteers. *P<0.05, compared to oral fasting: **P<0.01,
compared to oral fasting. Potassium output was not significantly different after the i.v
dose and the oral dose given with food.
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Figure 3.10. Mean urine flow rates induced by 40mg intravenous and oral frusemide
with and without food in 8 healthy volunteers. *P<0.01, compared to oral with food:
**P<0.05, compared to oral with food: ***P<0.05, compared to i.v. and oral fasting:
****P<0.05, compared to i.v.
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Urine volume (ml) (Thousands)
Figure 3.11. Total urine volumes over 8h following 40mg intravenous and oral
frusemide in 8 healthy volunteers. No significant differences were found.
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the intravenous dose of frusemide. Subject 1 felt slightly light-headed 1 h after
administration of the intravenous dose, when standing to pass urine The same subject
also complained of a headache after leaving the investigation room, having completed
the study. All these symptoms are known side effects of loop diuretics and can be
explained by the fluid and electrolyte disturbances caused by frusemide.
Section 3.4. Discussion
Intravenous dose
The pharmacokinetics of frusemide in healthy volunteers have previously been studied
by several investigators and are marked by a large degree ofvariability (Andreasen etal.
1982; Chennavasin etal. 1981; Cutler and Blair, 1979; Grahnen etal. 1984; Kelly et al.
1973; Smith et al. 1980; Waller et al. 1982,1988). These discrepancies in frusemide
kinetics occur partly because of the different methods employed to derive the
pharmacokinetic values, in addition to differences within and between subjects, study
protocols and assaymethods used.
After an intravenous dose of frusemide, plasma concentrations have been modelled
using 1, 2 and 3 exponential terms (Cutler and Blair, 1979; Hammarlund et al. 1984;
Kelly et al. 1973; Waller et al. 1982). Specifically the weighting factor used in fitting
these models has been found to greatly influence the final parameter estimates, especially
terminal half-life (Chennavasin et al. 1981).
In the present study individual data were best fitted using a biexponential equation with
weighting factor 1/y". The results, with a mean half-life of 96 mins, total clearance of
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147.7 ml/min, renal clearance of 99.1 ml/min and volume of distribution of 0.27 L/kg,
are in agreement with previously reported data( See Table3.5).
Oral doses
The extent oforal frusemide absorption in normal subjects appears to be independent of
dosageform i.e. solution versus tablet (Kelly etal. 1973;Waller etal. 1982). Waller etal
(1982) and Hammarlund et al (1984) have found differences in the rate of frusemide
absorption between solution and tablet form. They also observed considerable
interindividual variation in the shapes of plasma concentration time curves for tablets
given in the fasting state. Clinical evidence does seem to support the therapeutic benefit
ofadministration of frusemide as a solution especially in patients with congestive heart
failure (Niazovt7 al. 1985).
In the present study frusemide was administered orally as a solution in order to eliminate
the added variable of drug dissolution. Using this dosage form very little variation was
observed between subjects in the shapes of the plasma concentration time curves
following administration in the fasting state.
Food intake however produced a dramatic change in the shapes of the plasma
concentration time curves with a significant reduction in Cmax and a delay in Tmax.
Absolute bioavailability of frusemide was significantly reduced by approximately 30 %,
as judged from both plasma and urine data.
These results contrast with those obtained by Kelly et al (1973) and Hammarlund et al
(1984), both ofwhom found no significant difference in the bioavailability of frusemide
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Abbreviations:F=luorometric;TLChilayerchro atography;C GGiquidchromatography;HPLC=ighperformanceli i chromatography.
given with and without food.
The study by Kelly et al (1973) was however terminated 4 h after frusemide
administration thereby making calculations of AUC() inaccurate, especially for the
dose administered after food. The assay used was also much less sensitive and there
were highly variable results in the 24 h frusemide excretion.
Hammarlund et al (1984) , using a very similar breakfast to Beermann and Midskov
(1986), did find a reduction in AUC compared to the fasting dose, although the
difference did not achieve significance. On the other hand, Hammarlund et al( 1984) did
find a significant fall in the urinary recovery of frusemide. Beermann and Midskov
(1986) suggested that the lack of a significant difference in AUC when frusemide was
administered with and without food may have been a Type 2 error.
The significant reduction in the bioavailability of frusemide solution given with food in
this study however, strengthens the findings ofBeermann and Midskov (1986) who also
found that a meal decreased the bioavailability of a frusemide tablet by 30 %. Taken
together these results suggest that the reduction in bioavailability is not related to
dissolution problems of frusemide in the presence of food. A number of other factors
may however be responsible:
(1) Prolongation ofgastric emptying time
A predominant effect of food is inhibition of stomach emptying, due, primarily to
feedback mechanisms situated in the small intestine (Toothaker and Welling, 1980;
Ponto and Schoenwald, 1990). However Beermann and Midskov (1986) also found an
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almost identical reduction in frusemide bioavailability when the drug was given with a
heavy meal indicating that the effect was not caused by stomach emptying.
(2) Physical interaction
Absorption or adsorption interaction between frusemide and food components may
influence drug bioavailability.
(3) Metabolism
There is evidence to suggest that frusemide is metabolised in the stomach (Lee and
Chiou, 1983). If frusemide remains in the stomach for a longer period, as when
administered with food, this metabolism may be increased thereby reducing the amount
of intact frusemide available for absorption.
Response tofrusemide
In spite of the pronounced differences found in the extent ofabsorption and excretion of
frusemide between the intravenous and oral doses, no significant difference in total
sodium and water excretion was found. Some caution must be taken when comparing
these results since basal sodium excretion rates were not determined.
However, this type of discrepancy between the total amount of frusemide excreted and
the total effect has been observed previously by several other investigators. Branch etal
(1977) and Kelly et al (1973) found equivalent responses for 80 mg frusemide
administered orally and intravenously despite the lower bioavailability of frusemide or
less frusemide being excreted after the oral dose. Kaojarern et al (1982), after obtaining
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a similar response, proposed that the time course offrusemide delivery to its luminal site
of action may influence the total response independent of the total amount of drug
excreted. They calculated a maximally efficient excretion rate for frusemide and found
that oral administration maintains the drug close to this amount more persistently than
the intravenous dose.
Another possible explanation of the results may be that the more sustained urinary levels
of frusemide found after administration with food, may interrupt a period of relative
sodium retention (i.e. acute tolerance). The development of acute tolerance with
frusemide is believed to be due to activation of renal compensatory mechanisms
(Hammarlund etal. 1985; Sjostrom elal. 1988b). Hammarlund et al (1985) suggested
that direct isovolumetric substitution of urine losses produces little or no tolerance.
However Li el al (1986), using the dog as a model, showed that no fluid replacement or
100 % replacement with 5 % dextrose in water after intravenous frusemide both
produced the same degree of acute tolerance in natriuresis indicating the insignificance
ofwater compensation in tolerance development.
Overall, the results from this study not only underline the importance of carrying out
drug bioavailability studies in fasting and non-fasting states but also the importance of
determining whether any alteration in drug kinetics produces a change in drug response.
Having said this, these results were obtained in healthy volunteers receiving a single dose
of frusemide immediately after a standard breakfast with replacement of urine losses.
They are therefore still not easily applicable clinically where patients usually receive
frusemide long term and may ingest it together with food in a more random manner.
108
CHAPTER 4
EFFECTS OF FOOD ON THE BIOAVAILABILITY OF BUMETANIDE
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Section 4.1. Introduction
Bumetanide is a natriuretic and diuretic agent belonging to the same class of "loop
diuretics", as frusemide. Bumetanide is however 40-60 times more potent than
frusemide on a weight basis (Asbury eta]. 1972; Brater etal. 1983a; Davies etal. 1974;
Murdoch & Auld, 1975; Ramsay et al. 1978) and has a greater bioavailability of
approximately 80 % versus 50 % (Brater et al. 1983a; Holazo et al. 1984; Cook et al.
1988).
The previous study has shown that the absorption of frusemide in healthy volunteers is
grossly impaired when administered with a standard breakfast. Little evidence exists as
to whether the absorption of bumetanide is similarly affected by the presence of food.
Homeida et al (1976) did find a delayed response to oral bumetanide when given to
healthy volunteers after a meal, but no pharmacokinetic data were reported.
The aim of this study was to determine whether the bioavailability of bumetanide was
altered when administered with food.
Section 4.2. Methods
Subjects
Nine healthy male volunteers aged 19 to 36 years (27 ± 5 yr) and weighing 53 to 79 kg
(67 ± 7 kg) took part in the study. Subjects 1, 2 and 6 had participated in the previous
frusemide study. All volunteers were healthy according to medical history, clinical
examination and haematologicaland biochemical tests. They were negative forHIV and
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Hepatitis B antigen. All volunteers were informed of the nature of the study and each
gave written informed consent. The study was approved by the Lothian Health Board
Healthy Volunteers Studies of Ethics of Medical Research Sub-Committee. The
volunteers were asked to:
(1) avoid alcohol for 24 h before each study day
(2) avoid taking any othermedication for 1 week prior to and throughout the study
(3) fast from 22.00 h the night before each study day
Procedure
The nine volunteers received bumetanide 2 mg solution (0.5 mg/ml "Burinex" injection)
intravenously and orallywith and without breakfast exactly as described for frusemide in
Chapter 3, Section 3.2.
Venous blood samples were taken just before dosing and at 5, 10, 15,30,45, 60, 90, 120,
150, 180 min and hourly for the next 5 h after intravenous administration. After an oral
dose samples were taken at 0, 10, 15, 30, 45, 60, 90, 120, 150, 180 min and hourly for
the next 5 h. All samples were collected in lithium heparin tubes and centrifuged at
3000 rpm for 15 minutes. Plasma was stored at -20°C.
Urine was collected half-hourly for the first 3 h and then hourly up to 8 h for both
intravenous and oral studies. Volunteers also completed an 8-24 h urine collection at
home. Urine volumes were recorded and aliquots stored at -20°C until analysis.




Concentrations ofbumetanide in plasma and urine were measured by high performance
liquid chromatography with fluorescence detection as described in Chapter 2. Urinary
sodium and potassium concentrations were analysed by ion specific electrodes.
Pharmacokinetic analysis
Plasma concentration time data were analysed using the "Siphar" curve fitting and
modelling program.
Plasma concentration time curves following intravenous administration were best
described by a two compartment model comprising distribution and elimination phases
according to Equation 2.14. Following oral bumetanide administration in the fasting
state plasma concentration time curves were fitted to a one compartment model with 2
phases according to Equation 2.12. Plasma concentration time profiles for oral
administration with food could not be fitted to the model because of irregular
absorption. The trapezoidal rule was used to calculate AUC() ^ ^ for these data and the
area beyond the last measured concentration (C() to infinity was estimated according to:
AUC =C / k
t-oo t el
where k = intravenous elimination rate constant.
el
Statistics
All data are expressed as mean ± standard deviation (s.d.) unless otherwise stated.
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Analysis of variance was used to determine statistical differences between doses and
P<0.05 was accepted as significant.
Section 4.3. Results
In travenous administralion
The mean plasma concentration time plot for bumetanide following intravenous
administration is shown in Fig 4.1. Bumetanide concentrations could only be measured
up to 5 h in all individuals. The mean elimination half life was 67 ± 11 min (Table4.1).
The observed total plasma clearance (CL) for bumetanide was 202.8 ± 52.3 ml/min
(Table 4.2). Renal clearance (CLr) contributed 71.4 ± 8.4 % to the total body clearance
ofbumetanide. Non renal clearance (CL ) was 58.6 ± 22.2 ml/min. The mean volume
ofdistribution was 19.03 ± 3.95 L or 0.28 ±0.07 L/kg.
The mean area under the curve after intravenous bumetanide was 175.4 ± 45.0 gg.h/1.
The total amount of unchanged bumetanide excreted in the urine over 24 h was
1.43 ±0.17 mg or 71.4 ± 8.5 % of the administered dose. Although urine was collected
up to 24 h, bumetanide could not be detected after 8 h, except in one subject.
Oral administration
Mean plasma concentration time curves for oral doses given with and without food are
shown in Fig 4.2. Individual plasma concentration time curves are shown in Fig 4.3.
Food altered the shapes of the curves by reducing Cmax and prolonging Tmax, in most





Figure 4.1. Mean plasma concentrations following intravenous administration of 2 mg
bumetanide over 5 minutes to 9 healthy volunteers. Bars = ± s. d.
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Table 4.1. Pharmacokinetic data ofbumetanide 2 mg given intravenously (mean±s.d.).
Intercept/ Parameter Half-life





B (ng/1) 50 ± 10
67 ±11
Kel (H"1) 0.64 ±0.11
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Figure 4.2. Mean plasma concentrations following oral administration of 2 mg





Figure 4.3. Individual plasma concentrations following oral administration of 2 mg
































































































peak plasma concentration of 96.9 ± 15.1 pg/1 occurred 0.53 ± 0.08 h after oral
administration of bumetanide in the fasting state. Cmax was significantly reduced to
36.1 ±11.5 pg/1 (P<0.001) and Tmax delayed to 1.36 ± 0.72 h (P<0.05) following
administration with food. However no significant difference was found in mean AUC& 0-cc
values for the oral doses given with (126.5 ± 24.8 pg.h/1) and without (143.2 ±
23.0 pg.h/l)food.
Bioavailability
The bioavailability of oral bumetanide was calculated using Equation 2.10. Results are
given in Table 4.4. The bioavailabilities ofbumetanide given with and without food were
74.8 ± 15.5 and 83.7 ± 12.4 %, respectively. This difference was not statistically
significant, although there was a tendency towards lower values after food intake.
Renalelimination
Urinary recoveries of bumetanide following oral and intravenous administration are
shown in Fig 4.4. Over the first 2 h, urinary recovery was significantly higher for the
intravenous dose compared to the oral doses given with and without food. Recovery
was also significantly higher for the oral fasting dose compared to the dose administered
with food, over the same period. However from 2-8 h, recovery of bumetanide was
significantly higher following oral administration with food compared to the intravenous
and oral fasting doses. Urinary excretion of oral bumetanide was virtually complete 8 h
after drug administration. From 8-24 h urinary bumetanide could only be detected in 3
subjects following the oral fasting dose. This represented 1.7 ±1.1 % ofthe total amount
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Table 4.4. Bioavailability of2 mgoral bumetanide administered with and without






Without food With food
1 170.7 96.5 76.5
2 119.2 97.7 94.2
3 155.5 86.0 96.6
4 172.5 95.5 64.9
5 113.5 84.7 85.6
6 158.1 90.4 70.0
7 208.0 64.9 50.8
8 262.1 63.9 53.8
9 219.5 73.9 81.6
Mean 175.4 83.7 74.8

















a Oral 4- food
□ Oral fasting
□ I.V.





Figure 4.4 Urinary recoveries ofbumetanide following 2mg intravenous and oral doses
with and without food in 9 healthy volunteers. *P<0.01, compared to oral fasting:
**P<0.001, compared to oral with food: ***P<0.001, compared to i.v. and oral fasting.
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ofdrug excreted unchanged. After the oral dose given with food, bumetanide could be
detected in 6 out of the 9 subjects and represented 2.6 ± 1.8 % of the total bumetanide
recovered.
Mean total urinary recovery of bumetanide during 24 h (Fig. 4.5) following oral
administration with and without food averaged 50.1 ± 15.6 and 59.7 ± 8.4 %,
respectively. The difference was not statistically significant. Both recoveries were
lower than with the intravenous dose (71.4 ± 8.5 %).
The bioavailability of bumetanide was also calculated from the urinary recovery using
Equation 2.11. Bioavailability was 84.3 ± 8.3 % when administered in the fasting state
and 70.5 ± 22.2 % when administered with food. These values are not significantly
different from those calculated using AUC
O-oo
No significant differences were found in the renal clearance of bumetanide for the oral
doses given with and without food and the intravenous dose (Table 4.2).
Sodium excretion
Urinary excretion of sodium, potassium and water following administration of
bumetanide are only reported for the first 8 h of the study. All volunteers then went home
and fluid intake was not standardised.
Mean sodium excretion rates and total urinary sodium output following intravenous and
oral administration ofbumetanide are shown in Figs. 4.6 and 4.7.




Figure 4.5. Total urinary recovery of bumetanide over 24h (% of administered dose)
following 2mg intravenous and oral doses with and without food in 9 healthy volunteers.
*P<0.01, compared to oral fasting and oral with food.
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Figure 4.6. Mean sodium excretion rates induced by 2mg intravenous and oral
bumetanide with and without food in 9 healthy volunteers. *P<0.05, compared to i.v.:
**P<0.00l, compared to oral with food: ***P<0.0l, compared to oral with food:
****p<0 001, compared to i.v. and oral fasting.
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Sodium output (mmol)
Figure 4.7. Total sodium output over 8h following 2mg intravenous and oral
bumetanide with and without food in 9 healthy volunteers. *P<0.01, compared to i.v.:
**P<0.001, compared to i.v. No significant difference was found between the oral
fasting and oral dose given with food.
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Over the first 2 h sodium excretion rate was significantly higher for the oral fasting dose
compared to the intravenous dose and the dose administered with food. In the same
period, sodium excretion rate was also significantly higher for the intravenous dose
compared to the oral dose given with food. However from 2-6 h sodium excretion rates
following oral administration with food were significantly higher compared to both the
intravenous and oral fasting doses.
Over 8 h, total sodium output was found to be significantly higher for both oral doses
compared to the intravenous dose.
Urine flow rale
A similar pattern of response was obtained for urine flow rates following intravenous
and oral bumetanide (Fig. 4.8). The oral dose produced a significantly higher urine flow
rate over the first 2 h compared to the intravenous dose and the oral dose given with
food. From 2-4 h urine flow rate was higher for both the oral doses compared to the
intravenous dose and from 4-6 h it remained significantly higher for the oral dose given
with food.
Total urine volume over 8 h (Fig. 4.9) was significantly higher following the oral doses of
bumetanide given with and without food compared to the intravenous dose.
Potassium excretion
Mean urinary potassium excretion rates following intravenous and oral bumetanide
administration are shown in Fig. 4.10. During the first 2 h no significant difference in
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Figure 4.8. Mean urine flow rates induced by 2mg intravenous and oral bumetanide with
and without food in 9 healthy volunteers. *P<0.01, compared to oral with food:
**P<0.05, compared to i.v.: ***P<0.01, compared to i.v.: ****P<0.05, compared to
i.v.
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Urine volume (ml) (Thousands)
Figure 4.9. Total urine volumes over 8h following 2mg intravenous and oral bumetanide
with and without food in 9 healthy volunteers. *P<0.01, compared to i.v. Urine volume
was not significantly different after the oral fasting dose and the oral dose given with
food.
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Figure 4.10. Mean potassium excretion rates induced by 2mg intravenous and oral
bumetanide with and without food in 9 healthy volunteers. *P<0.001, compared to i.v.
and oral fasting: **P<0.05, compared to oral fasting: ***P<0.01, compared to oral
fasting: ****p<0.05, compared to oral fasting.
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Potassium output (mmol)
Figure 4.11. Total potassium output over 8 h following 2 mg intravenous and oral
bumetanide with and without food in 9 healthy volunteers. *P<0.01, compared to i.v.
and oral fasting. No significant difference in potassium output was found between the
i.v. and oral fasting doses.
133
potassium excretion was found. From 2-4 h potassium excretion rate was higher for the
oral dose given with food compared to the intravenous and oral fasting doses and from
4-8 h it remained higher compared to the oral fasting dose.
Total potassium excretion over 8 h (Fig. 4.11) was significantly higher for the oral dose
given with food compared to the oral fasting and the intravenous dose.
Section 4.4. Discussion
Intravenous administration
A variety of pharmacokinetic models have been used to describe the disposition and
elimination of bumetanide in healthy volunteers (Table 4.5). Halladay et al (1977)
described the elimination of bumetanide using a one compartment model, while Davies
et al {1974) used a two compartment open model. Pentikainen et al (1980), who was
able to measure 14C-bumetanide in plasma for up to 10 h, reported that plasma
concentration time data were best described in terms of a three compartment model.
However because the percent of drug eliminated during the last exponential phase is
small (17-20%), a two compartment model is most often utilised.
In the present study a biexponential equation was used to describe the pharmacokinetics
ofbumetanide following intravenous infusion. Using this model the terminal elimination
half life was 67 ± 11 min. This was of the same magnitude as that reported by others who
used either one or two compartment models (Table 4.5). Bumetanide half life was found
to be approximately three time longer (181 min) by Pentikainen et al (1980) who
adopted the three compartment model. However they stated that the half life of the
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second phase, 46 min, may be considered as the true elimination tt/ since most of the
drug was eliminated during that phase.
Following intravenous bumetanide, renal elimination was found to be the major
elimination pathway. Renal clearance contributed 71 % to the overall elimination of
bumetanide. By contrast, some other studies (Table 4.5) have shown equal and
sometimes greater elimination ofbumetanide by non-renal pathways (Davies et al. 1974;
Dixon et al. 1976; Pentikainen et al. 1980). Evidence that hepatic metabolism and
biliary excretion contribute to the clearance ofbumetanide has been reported in previous
studies with 14C-labelled bumetanide (Pentikainen et al. 1977). After intravenous
administration, metabolites of bumetanide accounted for approximately 30-35 % of
total radioactivity excreted into urine (Pentikainen et al. 1977), whereas 10-20 % ofan
oral dose was recovered in the faeces, mostly in the form of alcohols (Halladay et al.
1975; Pentikainen c/a/. 1977).
The systemic clearance of bumetanide (202.8 ± 52.3 ml/min) was somewhat greater
compared to that found for frusemide in the previous study (147.7 ± 28.3 ml/min, Table
3.2), leading to the shorter half life ofbumetanide (67 min versus 96 min for frusemide).
The volume of distribution found for intravenous frusemide and bumetanide were
similar, 0.27 ± 0.10 and 0.28 ± 0.07 L/kg, respectively. The high degree of plasma
protein binding found for both drugs restricts the apparent volume of distribution
(Johnson & Johnson, 1990;Lau etal. 1986; Ponto & Schoenwald, 1990).
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Oral adm inistration
The extent of bioavailability of bumetanide from oral tablet and solution dosage forms
are equivalent (Holazo et al. 1984). Bumetanide was administered orally as a solution in
this study in order to make it comparable with the previous study involving frusemide.
«
Food significantly reduced the peak concentration ofbumetanide and delayed the time to
the peak concentration, thereby changing the shape of the plasma concentration time
curve. The mean bioavailability of oral bumetanide given in the fasting state, calculated
from both plasma and urine data, was 84 %. This was slightly, but not significantly
decreased by food. The urinary recovery of bumetanide given with and without food
were also found not to be significantly different. Compared with frusemide, the
bumetanide solution seems therefore to be affected to a lesser extent by the presence of
food. One explanation may be differences in the sites ofdrug metabolism. As mentioned
earlier, there is some evidence to suggest that frusemide metabolism may occur in the
stomach (Lee & Chiou, 1983). This metabolism may be increased when the drug is
administered with food since it remains in the stomach for a longer time. Bumetanide
metabolism is however known to be hepatic in origin (Pentikainen et al. 1977, 1985;
Schwartz, 1981).
Response to bumetanide
Although more bumetanide was excreted unchanged in the urine over 24 h following
intravenous administration, the total amount of water and sodium excreted was
significantly higher after oral administration. Even in the first 2 h of the study, mean
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urine flow rate and sodium excretion rate were significantly higher for the oral fasting
dose compared to the intravenous dose, despite approximately 24 % less drug reaching
the urine. This difference may be attributable to dissimilar prestudy conditions because
baseline sodium excretion rates were not measured before each treatment. However,
similar results have been reported by other workers. Marcantonio et al (1982) found
greater total water, sodium, and potassium excretion in 24 h after oral administration of
1 mg bumetanide compared to an equivalent intravenous dose. Holazo et al (1984)
demonstrated comparable cumulative diuretic activity following 1 mg intravenous,
intramuscular and oral bumetanide administration to normal subjects. Bumetanide has
also been found to elicit equivalent natriuresis and urine flow in patients with congestive
heart failure, whether given orally or intravenously and despite 20 % less bumetanide
reaching the urine after oral administration (Cook etal. 1988).
Similar observations were also found for frusemide in the previous study, with
equivalent response being found for oral and intravenous administration, again despite
less drug being excreted after the oral doses. Kaojarern et al (1982) calculated the
existence of a maximally efficient excretion rate for frusemide. As a result, if the drug
can remain close to this rate for a prolonged period during oral dosing, the same or
greater cumulative response can occur with less total drug reaching the urine. This may
also explain the larger response to oral bumetanide found in this study.
These results have shown the bioavailability ofan oral bumetanide solution is affected to
a lesser extent by the presence offood compared with frusemide. Conclusions about the
absorption of a certain drug cannot therefore be derived from studies with other, albeit
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related, compounds. However, a general assumption that the absorption ofbumetanide
in unaffected by food cannot be made since this study involved one preparation of the
drug given with and without a more or less standard breakfast. The impact of different
types ofmeals should also be tested.
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CHAPTER 5
TIME OF ADMINISTRATION OF FRUSEMTDE AND BUMETANIDE IN
RELATION TO FOOD IN HOSPITAL PATIENTS
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Section 5.1. Introduction
Frusemide and bumetanide are both commonly used in the treatment of congestive heart
failure and oedema associated with hepatic and renal disease (Ponto and Schoenwald,
1990; Ward and Heel, 1984). It has been shown that the absorption of frusemide is
greatly reduced when administered to healthy volunteers with food. Bumetanide
absorption seemed to be affected to a lesser extent.
The aim of this study was therefore to obtain information on the general use of frusemide
and bumetanide in two medical wards within the Edinburgh Royal Infirmary by
recording doses, routes of administration and in particular times of administration in
relation to meals. If, as seemed likely, the drugs were frequently given with meals, their
efficacy could be compromised.
Section 5.2. Methods
The study was approved by the Lothian Health Board Medicine and Clinical Oncology
Research Ethics Sub-Committee. The consultant physician in charge of the patients in
wards 23 and 24 of the Edinburgh Royal Infirmary were asked if their patients could
participate in the survey.
A questionnaire was used to collect patient information, a copy of which is given in
Appendix 1. Information was collected over a 3 month period and all evaluable patients
admitted to wards 23 and 24, who were receiving frusemide or bumetanide, were
studied once 24 -72 h after admission.
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The diagnoses and reasons for diuretic treatment were obtained from the patients
medical notes. The ward provided information on the other drugs the patient were
receiving together with doses, routes of administration and any dose changes in
frusemide or bumetanide since admission. After the early morning ward drug round, the
patients themselves were asked when they received their frusemide or bumetanide in
relation to breakfast. They were also asked at what time they usually took their diuretic
at home in relation to breakfast.
Section 5.3. Results and Discussion
The results of the survey are listed in Appendix 2 and summarised below. Over the 3
month period, 43 males and 32 females participated in the survey. Their average age was
75 ±9 years.
Reason fordiuretic
Most patients were being prescribed diuretics for major indications such as congestive
heart failure, pulmonary oedema and renal disease. In several cases the diuretics were
also prescribed for hypertension and ankle oedema not caused by heart failure or renal
insufficiency.
Frusemide
Sixty six out ofthe 75 patients were taking frusemide. Fifty of these patients were taking
the drug as a single earlymorning oral dose and in 96% of these cases the dose was 80 mg
or less. 13 patients were receiving divided doses of oral frusemide, an early morning
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dose and an equivalent or lower dose given at either 2, 4, or 6 pm. The remaining 3
patients were receiving intravenous injections offrusemide.
Bumetanide
Only 9 patients were taking bumetanide. Five were taking a single oral dose and 4 were
taking bumetanide twice daily. Three patients who were being prescribed bumetanide at
home were prescribed an equivalent dose offrusemide while in hospital.
Dose changes in diuretic since admission
Nine patients who had been admitted with pulmonary oedema and congestive heart
failure received intravenous frusemide before being prescribed oral doses. In one of
these patients the intravenous dose was administered as an infusion over 1 h. In order to
obtain adequate diuresis, several patients also had their oral dose of diuretic increased
while in hospital.
Otherdrugs
Most patients were being prescribed several other drugs and in the majority of cases at
least one ofthe drugs was being taken at the same time as frusemide.
Timeofdiuretic administration in relation to breakfast
In the medical wards of the Edinburgh Royal Infirmary the timing of breakfast often
coincided with the early morning drug round. The times of administration of frusemide





30-21 20-11 IO-O Breakfast O-l O 11-20 21-30
Minutes before Minutes after
Figure 5.1 Time ofdiuretic administration in relation to breakfast in 72 hospital patients
admitted to wards 23 and 24.
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patient took 10-15 minutes to eat their breakfast which usually consisted ofporridge or
cereal and toast or a roll with butter and jam. All ofthe 72 patients taking an oral dose of
diuretic had taken it within ± 30 minutes ofbreakfast and 83 % had taken the drug either
during breakfast orwithin ± 10 minutes ofthe start or finish ofbreakfast.
The patients were also asked when they normally took their diuretic at home in relation
to breakfast (See Fig 5.2). A similar pattern emerged with 74 % taking their diuretic
either with breakfast or within ±10 minutes of breakfast. However a larger proportion
ofpatients did seem to take fruseniide before breakfast when at home.
Overall, the majority of patients surveyed were taking a single oral dose of diuretic
(usually frusemide) with or very close to hospital breakfast. Since the absorption of
frusemide (and to a lesser extent bumetanide) has been shown to be grossly impaired
when administered with food in healthy volunteers, the survey therefore shows the
extent to which these drugs are taken in circumstances where reduced absorption may








30-21 20-11 IO-O Breakfast O-l O 11-20 21-30
Minutes before Minutes after
Figure 5.2 Time of diuretic administration at home in relation to breakfast.
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CHAPTER 6




Most pharmacokinetic studies involve healthy, young subjects given single doses of
drugs under ideal/controlled fasting conditions. In practice however, most drugs are
administered under nonfasting conditions to unhealthy elderly patients treated on a long
term basis.
Frusemide is widely used and it has previously been shown that its oral absorption is
reduced by approximately 30 % when given to healthy volunteers with food. Also, the
survey showed that it is given to hospital patients in a random manner often with or in
close proximity to breakfast. It is therefore taken in a situation which could potentially
alter its absorption and hence the diuretic response.
The aim ofthis study was to establish whether the absorption and effect offrusemide was
improved in hospital patients when the time of drug administration in relation to meals




Ten medical inpatients (6 male and 4 female) aged 55 to 77 years (average 70 ± 7 yrs)
from wards 23 and 24 of the Edinburgh Royal Infirmary were studied after giving
informed verbal consent. The details of the patients are given in Table 6.1. They were
given an information sheet which included a full description of the objective and plan of
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Diazepam 5mg at night
Dihydrocodeine 60mg bd
Glipizide 1 Omg everymorning
Innovace 20mg at night
Isosorbide mononitrate 60mg
Aminophylline 225mg bd
Senna 2 tablets at night
Tildiazem Retard 90mg bd
2 60 M 40
Atrial fibrillation
Aspirin 75mg every morning
Digoxin 125mg every morning
Diltiazem SR 90mg bd
Enalapril 1 Omg at night
Isosorbide mononitrate 40mg bd
3 71 M 80
Myocardial
infarction
Aspirin 75mg every morning
Enalapril 20mg at night
Isosorbide mononitrate 20mg bd
Senna 2 tablets at night




Co-proxamol 2 tabs 6-8 hourly
Enalapril 20mg at night
5 77 F 80
Left vetricular
failure
Digoxin 0.125mg every morning
Enalapril lOmg everymorning
Erythromycin 250mg qid
Isosorbide mononitrate 20mg bd
Senna 2 tablets at night




Diltiazem SR 90mg bd
Enalapril 20mg at night













7 74 F 120 Left ventricular
failure
Aspirin 75mg every morning
Enalapril 20mg everymorning
Paracetamol 1 g 6 hourly
Senna 2 tablets at night
8 74 M 80 Left ventricular
failure
Aspirin 75mg everymorning
Enalapril 20mg at night
Isosorbide mononitrate lOmgbd
Paracetamol 1 g 4-6 hourly
9 73 F 80 Chest tightness Aspirin 300mg everymorning
Enalapril 20mg at night
Isosorbide mononitrate 60mg bd
10 76 M 80 Left ventricular
failure
Dipyridamole 25mg tid
Enalapril lOmg at night
Salbutamol2mgbd
Note: bd = twice daily; tid = thrice daily; qid = four times daily
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the study and the study was approved by the Lothian Health Board Medicine and Clinical
OncologyResearch Ethics Sub-Committee.
All patients were receiving routinely a single oral dose ofat least 40 mg frusemide, in the
morning, while in hospital. They were receiving no other diuretic agents (e.g amiloride).
Patients were maintained on their normal doses of other drugs at the usual times
throughout the study. Any patients with impaired renal function (judged from creatinine
clearance) other than that due to cardiac failure and age were excluded from the study.
Patients with any acute illness (e.g. pneumonia) were also excluded.
Procedure
A randomised design was used. Each patient was studied on 2 consecutive days. On one
occasion the patient received his/her oral dose of frusemide as normal during the early
morning drug round (uncontrolled administration) and the time in relation to breakfast
was recorded. On the other study day the time of the frusemide dose was controlled in
relation to the time of breakfast. Frusemide was given 2 h after food intake (controlled
administration). The hospital breakfast consisted ofporridge or cereal and a roll or toast
with butter and jam/marmalade. On both study days the patients ate lunch and dinner as
usual.
On each occasion venous blood samples (10 ml) were taken via an indwelling cannula
immediately before and 15, 30, 45, 60, 90, 120, 150, 180, 240, 360 and 480 min after
frusemide administration. All samples were collected in lithium heparin tubes and
centrifuged at 3000 rpm for 15 min. Plasma was stored at -20°C.
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Patients emptied their bladders just before taking their dose of frusemide. Urine was
then collected from 0-2, 2-4, 4-6 and 6-8 h after dosing. Urine volumes were recorded
and aliquots stored at -20° until analysis.
Analysis ofsamples
Frusemide concentrations in plasma and urine were measured by high performance
liquid chromatography as described in Chapter 2. No interfering peaks from other drugs
were found in any of the patients plasma or urine samples. Urinary sodium and
potassium were analysed by ion specific electrodes.
Pharmacokinetic analysis
Due to the irregular absorption patterns of frusemide in most patients, plasma
concentration time curves were not fitted to the pharmacokinetic model by computer.
Instead, the AUCfi 8) were calculated using the trapezoidal rule (Equation 2.3).
Statistics
Statistical comparisons were made using the non-parametric Wilcoxon signed-ranks
test and values of<0.05 were accepted as significant.
Section 6.3. Results
The ten patients took their dose offrusemide within ±25 minutes ofbreakfast (See Table
6.2). The individual plasma concentration time curves for controlled and uncontrolled
frusemide administration are shown in Fig 6.1. Out of the 10 patients, 7 were taking
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Figure 6.1. Individual plasma concentration versus time curves following uncontrolled











80 mg of frusemide. The remaining 3 patients (numbers 2, 6 and 7) were taking 40, 40
and 120mg, respectively. The plasma concentrations obtained from these 3 patients
were normalised to 80mg so that all the results were comparable. The resulting mean
plasma concentration time curves are shown in Fig 6.2.
Cmax, Tmax and AUC() values are given in Table 6.2. In all patients peak plasma
concentrations were higher following controlled administration (P <0.05, compared to
uncontrolled administration). The time to peak concentration was reduced from 1.92 ±
1.01 h following uncontrolled administration to 1.45 ± 0.86 h following controlled
administration. The Tmax values were however not significantly different. Mean
AUC and AUC values following controlled administration (2.78 ± 1.52 and
0-2h 04 h & v
4.77 ± 2.16 mg.h/1, respectively) were significantly greater (P<0.05) compared to
uncontrolled administration (1.85 ± 0.96 and 3.75 ± 2.19 mg.h/1). The AUC werev ' 0-8h
greater following controlled administration of frusemide in subjects 2, 4, 5, 7, 8 and 10.
However, the overall mean AUC values for controlled and uncontrolled
0-8h
administration were not significantly different.
Renal elimination
The recoveries of frusemide after controlled and uncontrolled administration are shown
in Fig 6.3 and Table 6.3. Over the first 2 h the percentage of the frusemide dose excreted
unchanged was significantly higher following the administration of frusemide 2 h after
breakfast (P <0.05). From 2-4 and 4-8 h the differences were not significant compared
to uncontrolled administration. Total urinary recovery of unchanged frusemide was








Figure 6.2 Mean plasma concentration versus time curves following uncontrolled and
controlled administration offrusemide to 10 hospital patients. Bars = ± s.d.
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5.826 60 3.392 88 NS
Frusemide excreted (% dose administered)
Figure 6.3. Urinary recoveries of frusemide (% of administered dose) following
controlled and uncontrolled administration in 10 hospital patients. *P<0.05, compard to
uncontrolled administration.
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Table 6.3. Urinary recovery of frusemide over 8 h (% ofadministered dose)
following uncontrolled and controlled administration to 10 hospital patients.
Patient
*
















corresponds with the greater AUC values obtained for these subjects. However the
mean total urinary recoveries for controlled and uncontrolled frusemide administration
were not significantly different.
Response tofrusemide
Urine volumes and sodium excretion following controlled and uncontrolled
administration were compared by ratio (i. e. uncontrolled / controlled (U/C).
Urine volume
The average 8 h urinary volume ratio (U/C) was 0.99± 0.57. However over the first 2 h
following frusemide administration the U/C ratio for urine volume was 0.72 ± 0.40,
indicating a greater response after controlled administration. However the 95%
confidence interval (95% CI) for the mean value did contain 1.0 (0.39 to 1.01). The
ratios from 2-4 and 4-8 h were 1.32 ±0.91 (95% CI = 0.62 to 2.02) and 1.36 ± 1.31 (95%
CI = 0.36 to 2.37), respectively.
Sodium excretion
A similar pattern was found for sodium excretion. From 0-2 h the sodium excretion ratio
was 0.73 ± 0.41 (95% CI=0.41 to 1.03). From 2-4 and 4-8 h the ratios were 1.72 ± 1.58
(95% CI = 0.40 to 3.05) and 1.49 ± 1.03 (95% CI = 0.63 to 2.35). The mean 8 h sodium
excretion ratio was 1.14± 1.13, which was not significantly different from 1.0.
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Section 6.4. Discussion
The pharmacokinetics and pharmacodynamics of frusemide have previously been
investigated in healthy elderly subjects and patients with different pathology. Chaudry et
al (1984) studied the effects of intravenous frusemide on urine volume and sodium
excretion in healthy young and healthy elderly subjects under fasting conditions. Total
24 h response to frusemide showed no difference in the two groups, however the pattern
of response was different. Peak effect on sodium and water excretion was delayed and
reduced in the elderly subjects but the response was prolonged. Kerremans etal (1983)
carried out a similar study using intravenous and oral frusemide in aged patients with
varying diagnoses. All the patients had used frusemide for at least three months and
most used other drugs which were continued during the study. After frusemide
administration the patients were allowed to eat and drink as usual. Under these
conditions, the absorption of frusemide and its volume of distribution were virtually
unchanged compared to results obtained from healthy volunteers. Total plasma
clearance and renal clearance were however reduced leading to increased plasma levels
and AUC. In spite of this a reduction in the renal elimination of frusemide was
demonstrated together with a decreased response. Studies by Brater et al (1982a) and
Greither etal (1984) showed little ifany quantitative change in frusemide absorption in
hospital patients with heart failure compared to normal subjects. However Brater et al
(1984) subsequently showed delayed absorption of frusemide in heart failure patients
causing attainment of peak urinary excretion rates of diuretic two- to threefold lower
than in normal subjects. The pharmacodynamics of frusemide were also altered as
demonstrated by a blunting of the dose response relationship.
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In elderly patients, the response to frusemide may already be altered or diminished partly
by age and partly by disease. The presence of food is an added variable which could
further reduce frusemide absorption and response. In healthy volunteers, Hammarlund
et al (1984) found that food significantly delayed the absorption of frusemide by
approximately 60 minutes. Beermann and Midskov (1986) found a 30 % decrease in
frusemide bioavailability when administered with breakfast. We also found that the
bioavailability of frusemide was reduced significantly when given to healthy volunteers
with breakfast and our survey showed that the majority of patients took it with or close
to the time ofbreakfast.
In the present study administration of frusemide 2 h after breakfast produced
significantly higher peak plasma concentrations and tended to reduce the time to the
peak. AUC( and AUC were significantly greater following controlled
administration. The percentage of the dose excreted unchanged in the urine was also
significantly higher over the first 2 h following controlled administration. Over the same
period the natriuretic and diuretic response to frusemide was also generally higher
compared to uncontrolled administration although the result was not statistically
significant.
These results must be interpreted with caution since several other factors, in addition to
food, may be responsible for the changes described above. The time of frusemide
administration itself may have altered the time course of elimination and response.
During uncontrolled administration, frusemide was usually taken around 08.00 h, hence
the dose given 2 h after breakfast was given at approximately 10.00 h. Investigations in
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both animals and healthy adults have implicated possible diurnal variation in diuretic,
natriuretic and kaliuretic effects offrusemide (Hernial etal. 1988; Tateishi et al. 1988).
Sodium and water excretion was increased 2 h postadministration when frusemide was
administered at 0700 h as opposed to 1900 h. The authors hypothesised a difference in
frusemide excretion secondary to diurnal variation in frusemide metabolism, tubular
secretion and/or protein binding as a potential cause of the observed variation. It is also
possible that the differences merely reflected day to day variation in frusemide
absorption and response. The kinetics and the dynamics of frusemide should have been
studied on two separate occasions following controlled administration in order to
determine any influence ofdaily variation. Finally, when frusemide was administered 2 h
after breakfast the drug was also administered 2 h after the patients had taken their other
medication. This reduced the chance of not only food-drug interactions but also drug-
drug interactions. For example, coadministration of nonsteroidal anti-inflammatory
drugs with frusemide has been shown to reduce the natriuretic response (Daskalopoulos
etal. 1985;Patak etal. 1975;Planase/a/. 1983).
Overall however, we found no significant improvement in either AUC() , urinary
recovery of frusemide or total natriuretic or diuretic response over 8 h when frusemide
was administered 2 h after breakfast. Therefore, despite our findings in healthy
volunteers where food produced, on average, a 30 % reduction in the bioavailability of
frusemide, it seems that in everyday clinical practice frusemide absorption may not be
altered by breakfast to an extent where drug efficacymight be compromised.
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CHAPTER 7




Despite the widespread use of frusemide, little is known about the mechanism of its
absorption from the gastrointestinal tract in man. However evidence from animal
studies suggests that it may exhibit site specific absorption. Chungi et al (1979) on
administering buffered solutions of frusemide to different gastrointestinal sites ofthe rat
gut found rapid absorption from the stomach and slower absorption from the small
intestine. In a similar study carried out by Ritschel et al (1991) frusemide was also
shown to have an absorption window comprised of the upper gastrointestinal tract. In
addition they also found that an active transport mechanism may be partly involved in its
absorption, which is a saturable process (Rowland and Tozer, 1980). If this is also the
case in humans, it is possible that the absorption of frusemide may be dose-dependent.
Evidence of dose-dependency is usually assessed by increasing the dose of a drug and
after normalising the resultant plasma concentrations or amounts excreted to the dose
administered, observing whether such values correspond. When the values do not
correspond, dose-dependency is inferred.
In the following study we have therefore compared the absorption and elimination of
frusemide administered as an oral solution over the dosage range 10-80 mg in healthy
volunteers.
Section 7.2. Methods
Eight healthy males, aged 21-38 years (average 28 ± 5 yrs.) and weighing 51-83 kg
(average 70 ± 10kg) took part in the study. The volunteers were healthy according to
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history, clinical examination and haematological and biochemical tests. They were
negative for Hepatitis B and HIV infection. The protocol was approved by the Lothian
Health Board Healthy Volunteers Studies Ethics ofMedical Research Sub-Committee
and all volunteers gave informed written consent after the aim and procedure had been
explained.
No other medication was allowed for 1 week before and during the study. Alcohol was
prohibited from 24 h prior to and during the study. All the volunteers fasted from
10.00 pm. the night before each study day.
Procedure
"Lasix" injection solution (frusemide 10 mg/ml) was administered orally as 1 ml (10 mg),
4 ml (40 mg) or 8 ml (80 mg) diluted to a final volume of 100 ml with orange squash (Kia-
Ora). The container was rinsed with a further 100 ml of water and this was also
administered to the volunteer.
To compensate for fluid loss during the study, 500 ml of 0.9 % sodium chloride was
administered intravenously over the first hour. For the remainder of the study urine
volumes were replaced by a similar volume of 5 % dextrose again administered
intravenously.
The volunteers remained supine during the study and had nothing to eat or drink up to 5 h
after dosing. A light lunch was provided between 5 and 6 h.
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BloodSamples
Blood samples were collected through an indwelling cannula placed in a forearm vein.
Samples (10 ml) were taken just before dosing and at 10, 15, 30,45, 60, 75, 90, 105,120,
150, 180 minutes and hourly for the next 5 h after drug administration. All the samples
were collected in lithium heparin tubes and centrifuged at 3000 rpm for 15 min. Plasma
was stored at approximately -20°.
Urine collection
The volunteers emptied their bladders prior to drug administration. Urine was then
collected at 1,2, 3, 4, 5, 6 and 8 h after drug administration. The volunteers also
collected urine from 8 - 24 h at home. Urine volumes were recorded and an aliquot
frozen at -20° until assayed.
Analysis ofsamples
Frusemide concentrations were determined by high performance liquid chromatography
using fluorescence detection as described in Chapter 2.
Data Analysis
Plasma concentration time curves were fitted to a one compartment model with 2 phases
(Equation 2.12), using the "Siphar" curve fitting and modelling program. Renal
clearance (CL^) values were calculated using Equation 2.9. Peak plasma
concentrations (Cmax) and time to peak plasma concentrations (Tmax) were observed
from the measured plasma concentrations following drug administration.
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The AUC{) Cmax and Ae (total amount excreted unchanged in the urine from 0 - 24 h)
were normalised for dose by multiplying the values by 4 for the 10 mg dose and dividing
by 2 for the 80 mg dose.
Analysis ofvariance was used to make statistical evaluation of the data. A P value of less
than 0.05 was accepted as evidence ofa statistically significant difference.
Section 7.3. Results
Mean concentrations of frusemide in plasma resulting from the administration of 10, 40
and 80 mg are shown graphically in Fig 7.1. Normalised plasma concentrations are
shown in Fig 7.2. The resulting pharmacokinetic parameters obtained from the three
administered doses are given in Table 7.1. Dose normalised maximum plasma
concentrations were not significantly different for all three doses. The mean Tmax for
the 40 mg dose was 40 minutes. No significant difference was observed among the doses
although there was a tendency towards increasing Tmax values with increasing dose.
Dose normalised AUC() values were also not significantly different (Table 7.1).
The total mean amounts of frusemide excreted unchanged in the urine in 24 h were 4.1,
18.0 and 38.0 mg for the 10, 40 and 80 mg doses, respectively. Cumulative amounts of
frusemide excreted are shown in Fig 7.3. When the values were normalised for dose no
significant differences were found (Fig 7.4 and Table 7.1).
The renal clearances for the 10, 40 and 80 mg doses were 106.7 ± 39.8, 90.5 ± 32.0 and
99.0 ± 33.2 ml/min. These values were not significantly different. Hourly renal
clearances of frusemide for all the doses were constant over 8 h (See Fig 7.5).
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Frusemide plasma concentration (mg/l)
Time (h)
Figure 7.1. Mean plasma concentrations of frusemide in 8 healthy volunteers following
the oral administration of 10,40 and 80 mg.
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Frusemide plasma concentration (mg/l)
Time (h)
Figure 7.2. Mean plasma concentrations offrusemide normalised to the40mg dose after
administration of 10,40 and 80 mg to 8 healthy volunteers.
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Table 7.1. Mean (± s.d.) pharmacokinetic parameters following administration of














lOmg 0.47 ±0.16 0.56 ±0.22 0.71 ±0.28 4.06 ± 1.29 106.7 ± 39.8
40mg 2.33 ±0.54 0.65 ± 0.23 3.54 ±0.88 18.02 ± 3.37 90.5 ±32.0








2.13 ± 0.60 3.40 ±0.84 19.01 ±2.11
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Cumulative frusemide excretion (mg)
Time (h)
Figure 7.3. Mean cumulative amounts of frusemide excreted in the urine following
administration of 10,40 and 80 mg to 8 healthy volunteers.
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Cumulative fruSemrde excretlon (mg)
Time (h)
Figure 7.4. Normalised frusemide excretion following administration of 10, 40 and
















Figure 7.5. Mean hourly renal clearances following administration of 10, 40 and 80 mg
to 8 healthy volunteers.
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Section 7.4. Discussion
Dose-dependent kinetics are seen within the therapeutic dose range for drugs such as
phenytoin and salicylic acid (Rowland and Tozer, 1980). The pharmacokinetic
behaviour of two antibiotics, cefadroxil and amoxycillin, have also recently been
studied, since these drugs may be subject to active absorption from the intestine
(Sanchez-Pico et al. 1989) and active renal tubular secretion (La Rosa et al. 1982).
Garrigues et al (1991) showed that the absorption and elimination kinetics ofcefadroxil
were non-linear after oral administration in man. Normalised peak plasma
concentrations and areas under the plasma concentration time curves decreased
significantly with increasing dose. Its clearance was also shown to be concentration-
dependent. Chulavatnatol & Charles (1994) using amoxycillin showed that the fraction
of the dose excreted unchanged decreased from 0.5 after 97 mg to 0.23 after 3103 mg in
healthy volunteers. Sjovall et al (1992) administered increasing doses ofamoxycillin to
patients with ileostomy. In the urine 70 % was recovered at the lowest dose compared
with 23 % at the highest dose. Cook et a! (1988) has suggested the possibility that the
absorption of the other commonly used diuretic bumetanide may be dose-dependent.
They obtained 81 % bioavailability after a 3 mg dose. This value was less than the 89 %
mean bioavailability reported by Marcantonio et al (1982), who administered 1 mg and
greater than the 66 % bioavailability reported by Lau et al (1986) who gave a 5 mg dose
to healthy subjects.
In this study however there was no evidence for a significant dose-dependent effect on
frusemide absorption or disposition over the dosage range studied. Normalised 10 and
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80 mg frusemide plasma concentrations and amounts excreted were not significantly
different compared to the 40 mg dose. Renal clearance of frusemide also remained
constant which is indicative of linear pharmacokinetics i.e. no evidence of concentration
dependent (dose-dependent) renal clearances offrusemide.
It is possible that a dose effect may be seen with a wider dose range, however it would
not be possible to study this in healthy volunteers due to ethical considerations.
However its absorption kinetics are clearly linear over the range 10-80 mg, which
includes the most commonly used doses in clinical practice.
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CHAPTER 8
PENICILLIN AND FRUSEMIDE INTERACTION IN MAN
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Section 8.1. Introduction
It is not uncommon for patients to take several drugs simultaneously. Pharmacokinetic
drug interactions can therefore arise, where one drug affects the absorption,
distribution, metabolism or excretion ofanother.
Being a weak acid, with extensive protein binding, the majority of frusemide is thought
to reach its site ofaction in the kidney via the nonspecific organic acid secretory pathway
of the proximal tubule (Bowman, 1975; Cutler & Blair, 1979; Hook & Williamson,
1965). Many other acidic drugs are secreted by the same transport mechanism and
competition for renal secretion can occur. Both probenecid (Brater, 1978; Chennavasin
etal. 1979; Homeida etal. 1977; Honari etal. 1977; Odlind and Beermann, 1980) and
indomethacin (Data et al. 1978; Smith et al. 1979) have been shown to compete with
frusemide for secretion, resulting in decreased renal clearance of the drug.
Benzylpenicillin (penicillin G) has a similar half-life to frusemide and is removed by
proximal tubular secretion (Kampmann et al. 1972). It is therefore possible that
benzylpenicillin and frusemide may compete for renal secretion, however no studies
have been carried out to determine this possible interaction. Ifbenzylpenicillin alters the
renal clearance and excretion of frusemide, changes in the duration and magnitude of its
diuretic action may result. Benzylpenicillin is still widely used for the treatment of
infections caused by susceptiblemicroorganisms (Wise, 1982; Ball, 1982).
The purpose ofthis study was to determine iffrusemide and benzylpenicillin compete for
renal secretion and secondly to determine if any interaction alters the natriuretic and
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diuretic action of frusemide.
Section 8.2. Methods
Subjects
Eight healthy male volunteers aged 21 - 40 years (average 32 ± 7 yrs) and weighing 54 to
95 kg (average 77 ± 14 kg) were studied. They were healthy according to history,
clinical examination and haematological and biochemical tests. Volunteers were
excluded if they were allergic to penicillin or if they had any history ofasthma or eczema.
All volunteers were asked to avoid any other medication for 1 week prior to and
throughout the study. For 2 days prior to each study period they were asked to avoid
excessive intake ofdietary salt. Each volunteer was given a diet sheet for guidance (see
Appendix 3). Volunteers were also asked to avoid alcohol for 24 h before each study
day, avoid caffeine containing drinks (coffee, tea, cola etc.) from 18.00 h and fast from
20.00 h the evening before each study day. The study was approved by the Lothian
Health Board Healthy Volunteer Studies Ethics of Medical Research Sub-Committee
and each volunteer gave informed written consent before taking part.
Procedure
Each volunteer was studied on 3 occasions at least one week apart, using a randomised
design. On each occasion the volunteer drank 200 ml ofwater at home at 07.00 h. At
approximately 08.00 h they attended the Clinical Pharmacology Unit, emptied their
bladders and drank a further 200 ml ofwater. An intravenous cannula (Venflon 2, 18G)
was then placed into a vein in each forearm, one for the administration of drugs and one
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for blood sampling. The volunteers remained recumbent for 1 h. The volunteers then
emptied their bladders again and received one of the following:
(1) 40 mg intravenous frusemide (10 mg/ml "Lasix" injection) - 4 ml frusemide injection
+ 46 ml 0.9% sodium chloride solution, infused at a constant rate over 10 min.
(2) 2.4 g intravenous penicillin (Benzylpenicillin sodium) dissolved in 45 ml of water
followed by 40mg intravenous frusemide (4 ml frusemide injection +1 ml 0.9 % sodium
chloride). Both were infused into the same arm according to the schedule shown in Fig.
8.1.
(3) Placebo (No drug control) - 50 ml of 0.9 % sodium chloride solution infused at a
constant rate over 10 min.
The vials of frusemide and penicillin used in the study contained different concentrations
ofsodium chloride. The solutions were therefore made up as described above in order to
ensure that the same amount of sodium (7.46 mmol) was administered during each
infusion. A total volume of50 ml was infused on each occasion.
On all 3 occasions, the volunteers drank 150 ml ofwater every half-hour for 6 h. A light
lunch was provided at the end ofeach 6 h study period.
Venous blood samples (5 ml) were taken from the opposite arm just before frusemide
and at 5, 10, 15, 20, 25, 30, 45, 60, 90, 120, 180, 240, 300, 360 min after frusemide
administration. Samples were collected in lithium heparin tubes and centrifuged at 3000
rpm for 15 min. Plasma was stored at -20°.
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4—44 4 PenicillinFrusemide infusedinfused overover 10min.min.
Figure8.1.Timschedulefopenicillina drusemidmin stration
On all three occasions urine was collected at 0, 1, 2, 3, 4, 5 and 6 h. Volunteers also
collected urine from 6 - 24 h at home. Urine volumes were recorded and aliquots stored
at-20° until analysis.
Analysis ofsamples
Frusemide concentrations in plasma and urine were measured by high performance
liquid chromatography and urinary sodium and potassium concentrations by ion specific
electrodes (Chapter 2).
Pharmacokinetic analysis
Following the intravenous infusion of frusemide plasma concentration versus time
curves were described by a 2 compartment model according to Equation 2.14. Data
were analysed by computer fitting using "Siphar". Total clearance and renal clearance of
frusemide were calculated using Equations 2.8 and 2.9. Non renal clearance was defined
as the difference between total and renal clearance.
Statistics
All data are expressed as means ± standard deviations (s.d.). Statistical significant
differences were determined using the Students t-test and Analysis ofvariance. P values




The pharmacokinetics of frusemide administered alone (F) and with penicillin (F+P) are
presented in Table 8.1. Total plasma clearance of frusemide was significantly reduced
when administered with penicillin (160.1 ± 30.7 for F and 132.6 ±22.4 ml/min for F+P,
P<0.05). The change in total clearance was due to a reduction in mean frusemide renal
clearance with penicillin (103.0± 15.9 for F versus 83.6+17.4 ml/min for F+P, P<0.05).
The reduction in renal clearance was however not persistent throughout the study.
Renal clearance values were only significantly reduced by penicillin over the first 2 h
compared to frusemide alone (Fig 8.2). The non renal clearance did not differ
significantly between treatments.
The reduced plasma clearance of frusemide administered with penicillin resulted in
slightly higher plasma concentrations of the diuretic at all time points, except over the
first 10 min (Fig 8.3). However, no significant difference was found in mean AUC (
(4.36+ 1.05 for frusemide alone and 5.16 + 0.79 mg.h/1 for frusemide and penicillin).
The urinary excretion rates of frusemide administered alone and with penicillin are
shown in Fig 8.4. A reduction in the urinary excretion rate of frusemide was found over
the first hour following administration with penicillin. For the remainder of the study
frusemide excretion rates were not significantly different. No significant difference in
total urinary recovery offrusemide over 24 h was found (Fig. 8.5.)
Mean plasma half-life was not significantly different following administration of
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Figure 8.2. Effect of penicillin on renal clearance of frusemide over time. *P<0.01,
compared to frusemide alone: **P<0.05, compared to frusemide alone. Bars =±s.d.
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Plasma frusemide concentration (mg/l)
Time (h)
Figure 8.3. Mean plasma concentrations following administration of frusemide alone
and with penicillin in 8 healthy volunteers. Bars=± s.d.
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Frusemide excretion rate (A'g/rnin)
Time (h)
Figure 8.4. Urinary excretion rate offrusemide administered alone and with penicillin in





Figure 8.5. Total urinary recovery of frusemide over 24h (% of administered dose)
following administration of frusemide alone andwith penicillin in 8 healthy volunteers.
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frusemide alone or with penicillin. The volume of distribution (Vd) was 0.18 L/kg; no
change occurred after penicillin.
Response tofrusemide
The time courses of frusemide induced sodium, water and potassium excretion are
shown in Figs. 8.6, 8.7 and 8.8. The effect of penicillin on total sodium, urine and
potassium output is shown in Figs. 8.9, 8.10 and 8.11.
Sodium excretion
Hourly sodium excretion rates remained constant following placebo (Fig 8.6). Sodium
excretion rates following intravenous frusemide were not altered by penicillin.
Following both frusemide alone and frusemide with penicillin, sodium excretion rates
peaked at 1 h and declined thereafter. 5 and 6 h after frusemide administration sodium
excretion rates were lower compared to those found during the placebo. Total sodium
output over 6 h were not significantly different following administration of frusemide
alone and frusemide with penicillin. Both were significantly higher compared with
placebo (Fig. 8.9).
Urine volume
During the placebo study urine flow rate increased slightly over the first 2 h but remained
constant over the next 4 h (Fig. 8.7). Following administration of frusemide alone and
with penicillin, urine flow rates were almost identical at all time points. Flow rates
peaked at 1 h, followed by a decrease during subsequent hours. Urine flow rates were
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Figure 8.6. Sodium excretion rates following administration of placebo, frusemide
alone and frusemide with penicillin in 8 healthy volunteers. *P<0.00l, compared to
control.
X Control (no drug)
-O Frusemide alone











X Control (no drug)
"Q" Frusemide alone
Frusemide + Pen G
Figure 8.7 Urine flow rates following administration of placebo, frusemide alone and
frusemide with penicillin in 8 healthy volunteers. *P<0.01, compared to control:
**P<0.05, compared to control
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Potassium excretion rate (mmol/min)
Time (h)
Figure 8.8 Potassium excretion rates following administration of placebo, frusemide
alone and frusemidewith penicillin in 8 healthy volunteers.
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Sodium output (mmoI/6h)
Figure 8.9. Total sodium output over 6h following administration ofplacebo, frusemide
alone and frusemide with penicillin in 8 healthy volunteers. *P<0.001, compared to
control.
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Urine volume (ml/6h) (Thousands)
Figure 8.10. Total urine volume over 6h following administration of placebo, frusemide




Figure 8.11. Total potassium output over 6h following administration ofplacebo, fruse-
mide alone and frusemide with penicillin in 8 healthy volunteers.
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lower compared to those found during the placebo study from 3 h onwards. Total urine
volumes over 6 h were not significantly different following administration of frusemide
alone and with penicillin (Fig. 8.10).
Potassium excretion
Potassium excretion rates were found not to be significantly different at any time point
over the 6 h study period following placebo, intravenous frusemide and intravenous
frusemide with penicillin. On all 3 occasions potassium excretion rates decreased from
baseline values over the first hour. Excretion rates did not show any increase following
frusemide administration, except at 3 h. Total potassium output over 6 h for placebo,
frusemide alone and frusemide with penicillin were not significantly different (Fig. 8.11).
Section 8.4. Discussion
Frusemide is a weak acid which is primarily excreted by proximal tubular secretion. The
substantial protein binding of the drug limits glomerular filtration (Cutler et al. 1974:
Cutler & Blair, 1979; Forrey etal. 1974). It might be expected that other organic acids
using the same transport system could inhibit frusemide secretion, reduce the amount in
the tubular lumen and hence reduce its diuretic effect. Potential drug-drug interactions
at this site have previously been evaluated using drugs such as probenecid and pentopril.
Probenecid is a known competitive inhibitor of secreted organic acids and was at one
time used in the hyperuricemia associated with frusemide therapy (Weiner et al. 1960).
In animals, coadministration of probenecid reduced frusemide secretion and attenuated
its natriuretic affect (Friedman et al. 1977; Hook & Williamson, 1965). However
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studies in healthy volunteers have resulted in contradictory results (Chennavasin et al.
l979;HomeidacTa/. l977;Honariefa/. 1977; Odlind and Beermann, 1979; Sommerse/
al. 1991). All the studies demonstrated a marked reduction in the renal clearance of
frusemide by probenecid. In some cases probenecid also decreased the nonrenal
clearance offrusemide (Chennavasin etal. 1979) or its volume ofdistribution (Homeida
etal. 1977). Odlind and Beermann (l 979) and Honari etal (1977) further demonstrated
that the reduction in renal clearance and excretion of frusemide caused by probenecid
attenuated the natriuretic effect. In contrast several other studies reported that sodium
excretion remained unchanged (Sommers et al. 1991; Smith et al. 1980) or even showed
an increase (Chennavasin et al. 1979; Brater, 1978) after probenecid, despite the
substantial reduction in the renal clearance and excretion of frusemide. Chennavasin et
al (1979) suggested that accumulation of frusemide in plasma from concomitant effects
ofprobenecid on its nonrenal clearance allowed more frusemide to appear in the urine at
later times, increasing response.
Tubular secretion also contributes significantly to the renal elimination of pentopril, an
angiotensin-converting enzyme inhibitor. The pharmacokinetic interaction of oral
frusemide and pentopril has been studied in 12 healthy volunteers (Rakhit et al. 1987).
Pentopril induced significant changes in the disposition of frusemide. Pentopril
decreased the renal clearance of frusemide by 54 % and the fraction excreted unchanged
by 55 %. This was compensated for by an increase in the metabolism of frusemide by
glucuronidation. However, in spite of the decreased renal clearance and urinary
excretion rate of frusemide, urinary output and sodium excretion remained almost
unchanged. One possible explanation was that total frusemide (unchanged and
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glucuronide) might contribute to diuresis and natriuresis rather than unchanged
frusemide alone. These studies show that drug interactions with frusemide at this site are
complex.
In the present study intravenous benzylpenicillin was found to reduce the renal clearance
of frusemide presumably by competing with frusemide for proximal tubular secretion.
The effect of benzylpenicillin on organic acid transport was however short-lived.
Urinary excretion of frusemide was only reduced by benzylpenicillin over the first hour
of the study, possibly because of more rapid elimination of penicillin. Frusemide non
renal clearance, volume of distribution and elimination half-life were not altered. The
interaction also had no effect on the total urinary recovery of frusemide or on the time
course and magnitude ofnatriuresis and diuresis.
In conclusion, the large intravenous dose of benzylpenicillin used in this study did not
affect the renal handling of frusemide to any great extent. In clinical practice,
benzylpenicillin is also usually administered intravenously because the absorption from
oral dosage forms is poor (Martindale, 1993). It is therefore unlikely that








Frusemide is usually administered either orally or as an intravenous bolus. In 1982
Kaojarern et al. demonstrated in healthy volunteers that virtually the same natriuretic
response was obtained whether the same dose of frusemide was administered
intravenously or orally, despite half as much unchanged drug being excreted after the
oral dose. They suggested that the time course ofdelivery of frusemide to the active site
was an independent determinant of overall response. Since then several reports in
healthy volunteers and patients have also shown that continuous intravenous infusion of
loop diuretics leads to increased diuretic and natriuretic effects compared to bolus
administration (Lahav et al. 1992; Lawson et al. 1978; Meyel et al. 1992; Rudy et al.
1991). One explanation is that the infusion may provide a more efficient rate of drug
delivery into the urine (Alvan et al. 1990; Meyel et al. 1992). In addition, the
administration of large single doses of diuretics can lead to the development of acute
tolerance. This is thought to be caused by compensatory renal sodium retention because
it occurs in response to excessive sodium excretion and is correlated with both the rate
and magnitude of natriuresis (Andreasen et al. 1989; Cook and Smith, 1987;
Hammarlund et al. 1985; Zhu & Koizum, 1987; Wilcox et al. 1983). Plasma
concentrations of renin and aldosterone increase consistently after frusemide (Mackay
etal. 1984; Riley et al. 1985; Sjostrom etal. 1988b; Wilcox etal. 1983) and it has been
proposed that the renin-angiotensin-aldosterone system (Figure 9.1) may play a role in
mediating the development of acute tolerance (Sjostrom el al. 1988b). One of the
effects ofangiotensin II is to increase the synthesis and release of aldosterone which in
turn increases sodium reabsorption. The development of this type of tolerance may
have been minimised by constant low dose infusion.
A prolonged low level response to frusemide may also be obtained if small repeated oral
doses were given at regular intervals. If this led to an increased total response an oral
sustained release preparation of frusemide may be beneficial To test this hypothesis we
compared the kinetic and the dynamic effects of a single oral dose of frusemide with an
equivalent oral dose administered at hourly intervals over 8 h in healthy volunteers.
Plasma renin activity (PRA) and aldosterone plasma concentrations were also measured




Eight healthy male volunteers, aged 25 - 36 years (30 ± 5 yrs) and weighing 55 - 96 kg
(77.3 ± 12.6 kg) participated in the study. They were healthy according to medical
history, clinical examination and haematological and biochemical tests. Each volunteer
gave informed written consent to the study, which was approved by the Lothian Health
Board Healthy Volunteer Studies Ethics of Medical Research Sub-Committee. The
volunteers were asked to observe the following whilst taking part in the study:
(1) avoid any other medication for 1 week prior to and throughout the study
(2) avoid excessive intake of dietary salt for 2 days prior to each study day. Each
volunteer was given a diet sheet for guidance (Appendix 3).
(3) collect urine for 24 h at home before each study period. This collection was
completed on arrival in the Clinical Pharmacology Unit and was used to assess sodium
and potassium excretion and thus approximate dietary intake ofsodium and potassium.
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Figure 9.1. Renin-angiotensin-aidosterone system in man.
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(5) avoid caffeine (coffee, tea, cola) from 18.00 h the evening before each study day
(6) fast from 22.00 h the evening before each study day
Procedure
A randomised, cross-over, single blind design was used. Each volunteer was studied on
2 separate occasions at least one week apart. At approximately 07.00 h the volunteers
drank 200 ml ofwater at home. One hour later they attended the Clinical Pharmacology
Unit. On arrival the volunteers emptied their bladders completely. This completed their
control 24 h urine collection. The volunteers were weighed and an intravenous cannula
(Venflon 2, 18G) was placed into a vein in one forearm, for blood sampling. Volunteers
then drank a further 200 ml ofwater and remained supine for 1 h. After 1 h 5 ml ofblood
was sampled for basal measurement of plasma renin activity and aldosterone. The
volunteers then emptied their bladders again before receiving one of the following:
(1) 40 mg oral frusemide solution (10mg/ml "Lasix" injection) as a single oral dose given
in 50 ml of orange squash (10 ml Kia-Ora orange squash + 40 ml of water). They also
received 50 ml oforange squash every hour for the next 8 h.
(2) 5 mg oral frusemide solution every hour for 8 h (1 Omg/ml "Lasix" injection). Hourly
doses were given in 50 ml of orange squash (10ml Kia-Ora orange squash + 40 ml of
water).
A low salt lunch was provided between 5 and 6 h after dosing and a light evening meal
was provided over the last hour of the study.
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FluidReplacement
Initially it was decided that fluid loss would be replaced orally with water according to
the volume of urine passed in the previous hour. Under these conditions 2 volunteers
started the study. However, because the volunteers passed such large volumes of urine
after frusemide they had problems consuming equivalent amounts of water. During
repeated dosing of frusemide, one subject also complained of a bad headache. He
experienced the same symptoms during single dose administration and could not drink
any more water after 7 h. At this point he decided to withdraw from the study.
The fluid replacement scheme was revised and the remaining volunteers repeated the
study receiving 100 ml ofwater every hour. Further problems were found. Following
the repeated doses of frusemide the volunteer experienced slight dizziness towards the
end of the study. 2 h after administration of the single dose the same volunteer nearly
fainted when standing to pass urine and needed to lie down. His standing blood pressure
was checked and was found to be low. The study was abandoned and the volunteer was
given 1000 ml of water to drink and 1 litre of 0.9 % saline was administered
intravenously. Larger volumes ofwater were therefore needed to compensate for fluid
loss.
The final fluid replacement scheme used for the 8 volunteers who participated in the





Venous blood samples (5 nil) were taken just before dosing and at 15, 30,45, 60, 75, 90,
105, 120, 180, 240, 300, 360, 480 and 600 minutes after administration of the single
dose. During repeated dosing blood sample (5 ml) were taken just before the first dose
and then every 30 minutes up to 10 h. Samples were collected in lithium heparin tubes
and centrifuged at 3000 rpmfor 15 min. Plasma was stored at-20°.
b) Plasma renin activity and aldosterone
On both occasions venous blood samples (5 ml) were taken every half-hour for the first
4 h and then hourly every hour up to 10 h. They were collected into tubes containing
200 gl of 5 % ethylenediaminetetra-acetic acid disodium salt (EDTA), which were kept
on ice. After centrifugation at 4 ° (2500 rpm for 20 min), the plasma was separated
immediately and stored at -40° until analysis.
Urine Collection
On both occasions urine was collected hourly until 10 h. After 10 h the volunteers went
home, with no restriction on fluid intake, and collected urine from 10 to 24 h. Urine
volumes were recorded and aliquots stored at -20° until analysis.
Analysis ofsamples
Frusemide concentrations in plasma and urine were determined by high performance
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liquid chromatography with fluorescence detection (Chapter 2). Plasma renin activity
and aldosterone concentrations were measured by radioimmunoassay (Chapter 2).
Urinary sodium and potassium were analysed by ion specific electrodes.
Analysis ofData
The AUC() values for single and repeated doses of frusemide were calculated using
the trapezoidal rule (See Chapter 2). Following the single oral dose, frusemide
concentrations in plasma could in general only be measured up to 5 h after dosing.
Plasma concentrations at 6, 8 and 10 h were estimated by linear regression.
Statistics
Data are expressed as means ± standard deviations (s.d.). Statistical comparisons were
assessed by the use of the Student t test for paired data with a P value of<0.05 accepted
as significant.
Section 9.3. Results
24 h sodium excretion values on the day prior to each study period were similar:
122.4 ± 30.0 mmol prior to the single dose of frusemide and 132.6 ± 37.2 prior to the
repeated doses. The corresponding potassium excretion rates were 53.4 ±22.1 and 53.8
±18.7 mmol and these differences were not significant.
Mean frusemide plasma concentration time curves and mean urinary frusemide
excretion rates following single and repeated doses are shown in Fig. 9.2. The AUC()
averaged 2.89 ± 0.66 mg.h/1 when frusemide was administered as a single dose
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Frusemide plasma concentration (mg/I)
Time (h)
Frusemide excretion rate (fJg/min)
Time (h)
Figure 9.2 Mean frusemide plasma concentrations (top graph) and mean urinary
frusemide excretion rate (bottom graph) after 40mg frusemide and 5 mg frusemide every
hourfor8h. Bars = ±s.d.
208
compared with 2.25 ±0.32 mg.h/1 when administered as repeated doses (Table 9.1.) The
difference was significant, P<0.05.
Urinary frusemide excretion rates following repeated administration increased up to 3 h,
remained fairly constant for the next 2-3 h and progressively declined thereafter. By
contrast, after the single dose a peak value of frusemide urinary excretion rate was
observed during the first hour, followed by a decrease during subsequent hours. The
total urinary recovery of frusemide over 24 h (Table 9.1.) following single and repeated
doses were 18.3 ± 3.3 and 16.4 ± 3.0 mg, respectively (P<0.05). This corresponds to
45.8 ± 8.3 and 41 0± 7.6% ofthe total dose administered.
FrusemideResponse
Cumulative urinary sodium excretion and mean sodium excretion rates following single
and repeated doses of frusemide are given in Figs. 9.3 and 9.4. Following the repeated
doses of frusemide, there was a tendency towards higher total sodium output over 10 h
compared to the single dose (Table 9.2). However the difference was not statistically
significant.
After the single dose of frusemide, urinary excretion of sodium (Fig 9.4) decreased to
below the baseline level by 5 h, indicating a period of net sodium retention. During the
repeated doses sodium excretion rate did not reach a peak until the third hour. A gradual
decline in natriuretic response then occurred, falling below baseline by 10 h.
Cumulative urinary volume and cumulative urinary potassium excretion are shown in
Figs. 9.5 and 9.6. No significant differences were found in total potassium excretion and
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Table 9.1. Area under the plasma concentration time curves and total urinary recovery








1 3.19 2.52 20.02 19.17
2 2.03 2.49 18.36 18.77
3 3.40 2.55 23.12 19.57
4 2.26 1.82 20.94 17.86
5 3.31 1.87 17.31 16.05
6 2.65 2.14 16.66 12.35
7 2.35 2.04 11.16 10.74
8 3.89 2.56 18.95 16.93
Mean 2.89 2.25 18.32 16.43
±s.d. 0.66 0.32 3.32 3.05
P <0.05 <0.05
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Urinary sodium excretion (mmol)
Time (h)
Figure 9.3. Cumulative urinary sodium excretion during lOh after single and repeated
doses of frusemide. Bars=±s.d.
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Sodium excretion rate (mmol/min)
Time (h)
Figure 9.4 Net urinary sodium excretion rate versus time. Response is represented by
urinary excretion rate over baseline. Values less than zero indicate sodium retention.
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Cumulative urine volume (L)
Time (h)
Figure 9.5. Cumulative urinary volume over lOh following administration ofsingle and
repeated doses offrusemide.
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Cumulative potassium excretion (mmol)
Time (h)
Figure 9.6. Cumulative potassium excretion over 1 Oh following administration ofsingle
and repeated doses offrusemide.
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urine output over 10 h following repeated and single doses offrusemide (Table 9.2)
Plasma renin activity (PRA) andAldosterone
PRA and aldosterone concentrations following single and repeated doses of frusemide
are shown in Figs. 9.7 and 9.8.
PRA
Basal measurements ofPRA were similar on both study days: 1.94 ± 1.00 prior to the
single dose and 1.91 ± 1.22 prior to the repeated doses. Following frusemide
administration large interindividual variation was found but different patterns in PRA
were evident. An early rise in PRA was found following the single dose of frusemide.
Concentrations peaked at 1 h and gradually declined over the next 3 h but did not reach
basal level PRA. A later smaller rise occurred at 6 h. By contrast, during the repeated
doses of frusemide , a more gradual increase in PRA was found. From 5-10 h PRA was
higher than after the single dose.
A Idosterone Concentrations
Plasma aldosterone concentrations followed a similar pattern to PRA during the single
dose of frusemide. With the repeated doses plasma aldosterone fluctuated around the
basal value showing an increase at 6 h.
SideEffects
Side effects consisted ofdizziness and headache. Subjects 2, 3 and 6 experienced slight
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Plasma renin activity (ng/ml/h)
Time (h)
Figure 9.7. Plasma renin activity during administration of single and repeated doses of
frusemide.
Plasma aldosterone cone (pg/ml)
Time (h)
Figure 9.8 Plasma aldosterone concentrations during administration of single and
repeated doses offrusemide.
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dizziness at the end of the study day following the single dose of frusemide. Subject 3
also felt dizzy 3-4 hours after the start of the repeated doses and complained of a
headache after 8 h.
Section 9.4. Discussion
The importance offluid and/or electrolyte replacement for urine loss in the evaluation of
diuretics has long been recognised (Branch et al. 1977; Hammarlund et al. 1985) and
various types of rehydration schemes have been used. Kaojarern et al (1982) and
Chennavasin et al (1980) employed intravenous isovolumetric replacement of all urine
losses with Ringer's solution. Brater et al (1983b) and Noormohamed et al (1991)
replaced urine volumes with equivalent amounts ofwater given orally. Li Kam Wa et al
(1991) administered 100 ml ofwater orally every hour; Rudy etal (1991) andMvknetal
(1988) administered 150 ml ofwater orally every hour; Hammarlund et al (1985) gave
200ml ofwater per hour. In the present study problems were encountered with two fluid
replacement schemes previously used by several other investigators (i.e. isovolumetric
replacement of urine losses with water and 100 ml ofwater administered every hour).
Using isovolumetric replacement of urine with water the volunteers were unable to
drink the large quantities required, whereas 100 ml of water every hour appeared
inadequate with one volunteer nearly fainting through a drop in blood pressure.
Problems such as these were not reported by other investigators.
Most drugs are still given by injection and as conventional tablets and capsules. Due to
its relatively short half-life, frusemide in these forms is short acting and potent which in
some patients may lead to excessive diuresis, side effects and inconvenience.
219
Frusemide delivery rate in the nephron has been reported to be one of the major
determinants of diuretic response (Kaojarern et al. 1982). According to this concept a
low but continuously effective urinary excretion rate of frusemide may lead to a higher
diuretic effect than short exposure of the active site to high concentrations of the drug.
Several studies have already investigated whether continuous infusion of loop diuretics
may be a more efficient way to administer this kind ofdrug.
In animals Lee et al (1986) compared different lengths of infusion time using the same
total dose of frusemide. They found increased diuretic effect with increasing infusion
times, whereas pharmacokinetic parameters were not significantly different between the
four infusion times (10 s, 30 min, 1 hand8h). Increased diuretic effects with increasing
infusion times were also reported when the same total dose of the loop diuretic
bumetanide was infused for 10 s, 1 h and 4 h. This occurred despite lower urinary
excretion ofunchanged bumetanide following the 1 and 4 h infusions (Ryoo etal. 1993).
In 1983, Copeland et al compared the diuretic effects of the same dose of frusemide
given by bolus and by constant infusion in 18 postoperative patients. A gentle sustained
diuresis was achieved by constant infusion, but no significant difference was found in
total urine volume and total sodium excretion compared with bolus frusemide
administration. However several subsequent studies demonstrated superior efficacy of
continuous intravenous infusion of loop diuretics. In all these studies the continuous
infusions were preceded by small loading doses but again the same total dose of
frusemide was administered compared to the bolus dose. Meyel et al (1992), in healthy
volunteers, found a greater response after treatment with continuous infusion compared
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to bolus injection, whereas total urinary frusemide showed no difference. Lahav et al
(1992) carried out a similar study in patients with congestive heart failure. The
continuous infusion produced diuresis and natriuresis that were significantly and
consistently higher than intravenous administration. Furthermore, the infusion induced
sustained diuresis with relatively little variation in urine output. Finally Rudy et al
(1991) demonstrated that continuous infusion of the loop diuretic bumetanide also
resulted in significantly greater net sodium excretion compared with bolus injection in
eight patients with chronic renal failure. The greater overall natriuresis with continuous
infusion compared to intravenous bolus injections may be attributed to the changed time
course ofdelivery offrusemide into the urine.
Based on these observations and the concept of Kaojarern et al (1982) we decided to
compare the effects of the same total dose of frusemide administered as a single oral dose
and as repeated doses over 8 h in order to determine the benefits of another alternative
and perhaps more efficient mode oftherapy, slow or controlled release tablets.
The average AUCq and total urinary recovery of frusemide over 24 h were found to
be significantly lower following the repeated doses. Despite less drug being delivered to
the active site no significant differences were found in total sodium, potassium and
water excretion compared to the single oral dose. This cannot be attributable to
dissimilar prestudy conditions since baseline sodium excretions were not significantly
different before each phase of the study. The low but more prolonged urinary excretion
rate of frusemide found during repeated administration may have produced more
efficient drug utilisation than the single dose. In other words, more sodium output
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relative to the excreted amount ofdiuretic drug.
After the single dose of frusemide sodium excretion rates fell below baseline at hour 5.
During repeated dosing a gradual decline in natriuretic response occurred after 3 h
despite the fairly constant urinary excretion offrusemide from 3-6 h. These data indicate
that compensatory mechanisms are invoked even after excretion of relatively small
amounts ofsodium. However sodium excretion rates remained above baseline up to 9 h
(2 h after the last dose) presumably because the diuretic was still being eliminated. The
renin-angiotensin-aldosterone system may be responsible, at least in part, for this
apparent rebound effect. Different trends in PRA and aldosterone were observed
following single and repeated frusemide administration which were consistent with
frusemide response. An early rise in PRA and aldosterone were found during the brisk
natriuresis following single dose administration whereas a gradual rise in PRA was
found following repeated administration which corresponds to the lower sodium
excretion rates and gradual decline in sodium excretion found during this dosage
regimen.
In conclusion, these results suggest that in terms of total diuretic and natriuretic
response an oral sustained release formulation would offer no advantage over
conventional tablets. No increased response was found using repeated dosing.
Repeated dosing did however avoid the peak diuresis associated with a single dose




FINAL DISCUSSION AND SUMMARY
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Final Discussion
An important prerequisite for all bioavailability/pharmacokinetic studies is an accurate
and reliable analytical method to measure drug concentrations in biological fluids. In the
case of frusemide, the controversy surrounding its stability in acidic conditions and in
light has led to the continued development ofvarious assays employing several different
extraction and detection techniques. Most have utilised liquid-liquid extraction for
sample clean up and high performance liquid chromatography with ultraviolet or
fluorescence detection which has provided good sensitivity and precision and fairly
consistent results. However the use of strong acids (e.g. hydrochloric acid) in some
liquid extractions together with long handling times and interfering endogenous peaks
on some chromatograms despite laborious extraction steps, suggest that it may not be
the most suitable procedure for the extraction of frusemide. To measure frusemide in
plasma a relatively new solid phase extraction technique was therefore chosen which
was developed by Russel et al in 1989 to try to circumvent some of these problems. The
procedure is based on the adsorption of frusemide on the surface of a reversed-phase
silica (C Bond Elut) column. Although the process was still fairly time consuming it18
did consistently yield final samples with few endogenous peaks, none ofwhich interfered
with frusemide or the internal standard, desmethylnaproxen. The process also proved to
be highly selective for frusemide since no additional peaks were found in our patient
samples despite the fact that they were all taking several other drugs. Frusemide
recoveries of over 90 % also indicated that there were no major problems with acid
hydrolysis or photochemical degradation during the extraction. Care was taken to
exclude light by using amber glassware. In terms ofsensitivity and accuracy, the method
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did not differ from other published liquid-liquid extractions methods. However good
linearity over the range 0.05 - 1 and 1 - 10 mg/1 and acceptable precision at or above 0.05
mg/1 (coefficient of variation less than 10 %) allowed for adequate quantification of
plasma drug concentrations following administration of both therapeutic doses of
frusemide (40 and 80 mg) and the low dose frusemide administered in the dose
dependent and single versus repeated dose studies.
A similar extraction procedure was deemed unnecessary to measure frusemide in urine
since good reproducibility and linearity were obtained by direct injection of urine onto
the high performance liquid chromatography column. The day to day coefficient of
variation varied between 4.3 and 1.4 % over the concentration range of 0.1 to 5.0 mg/1.
The statistical agreement of frusemide bioavailability calculated from both plasma and
urinary data in Chapter 3 suggest that plasma and urine determinations were both
reliable and consistent. The stability tests indicated that frusemide was stable in plasma
and urine frozen at -20°C for at least 8 and 10 weeks, respectively. All samples were
analysed well within this time period.
The assay ofbumetanide is more difficult due to the fact that plasma concentrations after
therapeutic doses are usually in the low ng/ml range. For plasma samples a method
developed by Wells el al in 1991 was used, which again comprised solid phase extraction
and fluorescence detection. Previous methods required large sample volumes,
cumbersome extractions and dual detection of bumetanide and the internal standard.
Compared to other assays it therefore provided a relatively simple approach to achieve
separation ofbumetanide without any loss ofsensitivity and precision. It was possible to
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measure concentrations as low as 2.5 ng/ml using 0.2 ml plasma samples, which was in
fact lower than the 5 ng/ml limit quoted by Wells etal (1991). The day to day precision,
as determined by coefficients of variation, did not exceed 8 % over the concentration
range studied. As with frusemide, direct injection ofurine samples provided satisfactory
precision (coefficient ofvariation < 5 %) and good linearity over the range 0.1 - 1 mg/1.
Bumetanide was stable in plasma and urine frozen at -20°C for up to 12 weeks and all
plasma and urine samples were analysed using the above method within one week
following collection.
Having set up reliable analytical methods to measure frusemide and bumetanide in
plasma and urine, one of the first objectives was to compare the common experimental
situation ofgiving these drugs in the fasting state with a clinically more relevant situation
i.e. when taken together with food. Previous similar studies with frusemide had
provided variable results (Beermann and Midskov, 1986; Hammarlund et al. 1984;
Kelly et al. 1973) and no such studies had been carried out with bumetanide.
Concomitant intake of breakfast delayed the absorption and significantly reduced the
bioavailability of a 40 mg solution of frusemide given to eight healthy volunteers.
Analogous results were reported by Beermann and Midskov (1986) who found that a
similar breakfast reduced the bioavailability of a 40 mg frusemide tablet by
approximately 30 % in healthy volunteers. The effect therefore appears to be
independent of formulation. This contrasts with other drugs such as nitrofurantoin
(Rosenberg and Bates, 1976), aspirin (Spiers and Malone, 1967; Volans, 1974) and
erythromycin (Hirsch and Finland, 1959; Hirschc/a/. 1960) where formulation has been
shown to have a pronounced effect on the extent of the drug-food interaction,
226
suspensions and effervescent forms of these drugs were much less susceptible to the
action offood that conventional tablets.
In contrast to the findings with fruseniide, the absorption of bumetanide solution in
healthy volunteers was delayed but not significantly reduced by the same breakfast. The
reason why food appears to interact differently with bumetanide and frusemide remains
unclear but may reflect differences in sites of absorption or metabolism. Other related
drugs whose absorption has been found to be affected differently by food intake include
bendroflumethiazide (Beermann et al. 1978) and hydrochlorothiazide (Beermann and
Groschinsky-Grind, 1978) and ampicillin (Welling, 1977b) and amoxycillin (Melander,
1978). The bioavailabilities of hydrochlorothiazide and ampicillin are increased and
reduced, respectively by food whereas it appears to have no influence on the absorption
of either bendroflumethiazide or amoxycillin. Irrespective of the mechanisms involved,
the lack of effect of food on bumetanide absorption may represent a therapeutic
advantage of this drug which also had a somewhat greater bioavailability than frusemide
(approximately 84 % versus 75 %). Although the bioavailability of oral bumetanide
compared well with values reported by other investigators (Brater et al. 1983a, 1984;
Cook etal. 1988;Holazoeta/. 1984; Marcantonio etal. 1982), frusemide bioavailability
was generally higher than most previously reported values. Although highly variable, its
bioavailability usually falls in the range 40 - 60 % (Beermann et al. 1975; Brater et al.
1982; Hammarlund et al. 1984; Kelly et al. 1973; Ponto and Schoenwald, 1990). The
higher bioavailability obtained in the present study may be due to administration of
frusemide as an oral solution. Clinical evidence does support the therapeutic benefits of
a liquid form of frusemide (content of vials for injection) given orally in patients with
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heart failure (Niazov et ah 1985) although previous studies in healthy volunteers have
suggested that tablet and solution forms of frusemide are equivalent in the extent of
absorption (Waller et ah 1982, 1988; Hammarlund etah 1984). In the above study oral
administration of bumetanide, irrespective of the presence or absence of food and
despite less drug reaching the urine, was also shown to elicit a greater pharmacological
response than intravenous bumetanide. This effect may be due to the maintenance ofan
effective plasma concentration of bumetanide for a longer period after oral than
intravenous administration.
One problem which arose in both of these studies was the inability to fit the plasma
concentration time curves following frusemide administration with food to the
pharmacokinetic model by computer due to the irregular absorption profiles. Instead,
the AUC
s] values were calculated using the trapezoidal rule. However the area
beyond the last measured concentration to infinity had to be estimated using the
intravenous elimination rate constant, assuming that the disposition kinetics of the drug
would be similar after oral administration, and that there would be no change beyond this
point. Because the potential error in doing this was small, this approach was felt to be
justified.
The majority of patients subsequently surveyed in the medical wards of the Edinburgh
Royal Infirmary were found to be taking a single early morning oral dose of frusemide
with or in close proximity to breakfast, a situation where efficacy could clearly be
compromised. However in spite of the findings in healthy volunteers, a standard hospital
breakfast appeared to have no significant adverse effect on the absorption of frusemide
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or its diuretic and natriuretic response in these patients. The lack of a significant effect
may reflect the rather small number ofpatients studied since the areas under the plasma
concentration time curve and urinary recoveries of frusemide were increased in six ofthe
ten patients when the dose was administered 2 h after breakfast. Day to day variation in
absorption and response may also have masked any significant improvement.
Absorption of frusemide, especially in heart failure patients, is known to be even more
erratic (Brater et al. 1982a, Greither et al. 1979). It is also possible that only certain
types of food affect the uptake of frusemide. This has previously been shown for other
drugs including paracetamol, the absorption ofwhich is delayed to the greatest extent by
a high fat breakfast (Jaffe et al. 1971; MacGilveray and Mattok, 1972; Walter-Sack et al.
1989; Wessels et al. 1992). Griseofulvin absorption is only increased by high fat meals,
most probably due to food induced enhancement of dissolution (Welling, 1977b), and
tetracycline absorption is reduced by calcium rich foods due to chelation with metal ions
(Neuvonen, 1976; Neuvonen and Turakka, 1974). The absorption of frusemide should
perhaps therefore have been tested in the presence of a high fat, a high carbohydrate and
a high protein meal to establish the degree of interaction with each. Further
investigations in larger patient populations are needed in order to fully determine the
effect offood on frusemide absorption and more importantly the diuretic response under
the usual clinical conditions of use. Overall however, these food-drug interaction
studies suggest that patients should perhaps take frusemide on an empty stomach or at
least in a standardised way in relation to meals in order to minimise variation in
absorption and response. On the other hand, because bumetanide absorption was much
less affected by food, there may be no need to control the time of its administration in
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relation to meals.
No dose-dependent effect on frusemide absorption could be demonstrated over a range
of doses commonly used in clinical practice as there were no significant differences in
normalised plasma concentrations or areas under the plasma concentration time curves
following administration of 10, 40 and 80 mg frusemide. Although it is impossible to
predict what might happen outwith this dose range, the results obtained tend to dispute
the evidence acquired in animals for site specific active absorption offrusemide (Chungi
et al. 1979; Ritschel et al. 1991) and hence the hypothesis that site specific absorption
may be one cause of the reduced bioavailability of frusemide (Ponto and Schoenwald,
1990). Other mechanisms, including poor solubility and presystemic metabolism, may
be involved (Lee and Chiou, 1983; Ponto and Schoenwald, 1990). The failure ofdose to
influence frusemide clearance indicates that the disposition kinetics of frusemide were
linear over the range 10-80 mg.
Early in vitro and in vivo animal studies demonstrated that frusemide exerts its primary
diuretic action from the luminal surface of the ascending limb of the loop of Henle by
inhibiting active chloride transport and thus preventing the reabsorption of sodium
which passively follows chloride. This in turn results in a pronounced diuresis (Burg,
1976; Odlind, 1979; Odlind and Beermann, 1980; Rose et al. 1976; Seely and Dirks,
1977). Subsequent drug interaction studies with probenecid in healthy volunteers
furthered the understanding of its mechanism ofaction. Pretreatment ofnormal subjects
with probenecid caused a significant reduction in the renal and nonrenal clearance of
frusemide and significantly increased plasma concentrations (Chennavasin et al. 1977;
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Homeida et al. 1977; Honari etal. 1977; Odlind and Beermann, 1979). Howeverwhile
causing a rightward shift in the relationship between serum concentrations offrusemide
and response, probenecid had no effect on the relationship between urinary frusemide
excretion rate and response (Chennavasin et al. 1979). The conclusions from such
studies was that the renal excretion of frusemide could be blocked effectively by
probenecid acting to compete for the nonspecific organic acid active transport system
situated in the proximal tubule. Also, the amount of frusemide delivered into the urine
was more directly related to response than serum concentrations of frusemide.
Therefore, agents which interfered with the renal tubular transport offrusemide should
antagonise its diuretic action.
It was shown here that intravenous benzylpenicillin (Penicillin G), a drug commonly
administered in large intravenous doses and which is eliminated from the body by active
proximal tubular secretion (Kampmannc?/ al. 1972; Martindale, 1993; Plautc/a/. 1969),
temporarily but significantly reduced the renal clearance and urinary excretion rate of
frusemide, presumably by competing with it for renal secretion. The short lived effect
was probably due to more rapid elimination of penicillin than frusemide, but this could
not be confirmed as the rate of removal of penicillin was not determined. Interestingly,
this pharmacokinetic interaction had no influence on either the rate or magnitude of the
natriuretic and diuretic response to frusemide. This lack of effect on the response to
frusemide was also found in some of the probenecid studies despite a much more
constant degree of inhibition (Homeida et al. 1977; Honari et al. 1977), and in several
instances the same total amount of frusemide in urine actually caused a greater overall
natriuretic response following the administration of probenecid (Brater, 1978;
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Chennavasine/a/. 1979; Sommers etal. 1991). This unexpected finding was attributed
to the changed time course of delivery of frusemide into urine (Brater, 1978, 1983;
Kaojarern a/. 1982).
In agreement with the principle that the time course ofdelivery is important, Meyel etal.
(1992) reported a significantly increased 8 and 24 h excretion ofsodium when frusemide
was given as a continuous infusion compared with an intravenous bolus injection of the
same total dose in healthy volunteers. Similar results were obtained in another study by
Lahav etal (1992) who demonstrated that continuous infusion of frusemide preceded by
a bolus dose produced significantly greater diuresis and natriuresis than an equivalent
total dose administered intermittently in patients with congestive heart failure. Based on
these data it was thought that small repeated oral doses of frusemide (5 mg every h for
8h) might possibly/conceivably lead to a greater net sodium excretion than the
equivalent single dose (40 mg). Although this hypothesis could not be substantiated in
the present study in healthy volunteers, the repeated dosing regime did produce at least
an equivalent diuretic and natriuretic response despite the delivery of significantly less
drug to the urine over 24 h compared to the single dose. This pattern of prolonged
delivery did seem therefore to produce a more efficient drug response. As discussed
earlier, a similar discrepancy was observed in the bumetanide study where oral
administration produced a greater pharmacological reponse than an equivalent
intravenous dose in spite of a lower 24 h urinary recovery of bumetanide. Although this
may be attributable to dissimilar prestudy conditions as no attempt was made to
standardise sodium intake, similar observations have been noted by other investigators
both in normal subjects (Holazo et al. 1984; Marcantonio et at. 1982) and in patients
232
with heart failure (Cook et al. 1988). These results seem therefore to provide further
evidence that the diuretic and natriuretic reponse to frusemide and bumetanide is not




1. Analytical methods developed by Russel etal( 1989) and Wells et al (1991) were used
to measure plasma concentrations of frusemide and bumetanide by solid phase
extraction, HPLC separation and fluorescence detection, respectively. The sensitivity,
reproducibility and linearity of these assays made them suitable for monitoring plasma
and urine frusemide and bumetanide concentrations.
2. In 8 healthy volunteers given 40 mg oral frusemide, breakfast dramatically changed
the pattern of the plasma concentration time curve compared to fasting administration.
Mean peak concentrations were significantly reduced (2.35 ± 0.49 to 0.51 ±0.19 mg/1)
and the mean time to peak concentration was delayed (0.69 ± 0.21 to 1.91 ±0.93 h)
indicating a reduced rate ofabsorption. Bioavailability, as judged from plasma and urine
data was significantly reduced by approximately 30%.
3. In a similar study with 2 mg oral bumetanide in 9 healthy volunteers, breakfast reduced
the mean peak plasma concentration from 96.9 ± 15.1 fasting to 36.1 ± 11.5 pg/1, and it
also delayed the mean time to peak from 0.53 ± 0.08 to 1.36 ± 0.72 h. Bioavailability
however was not significantly reduced by food (74.8 ± 15.5 with and 83.7 ± 12.4 %
without breakfast).
4. A survey of the timing of administration of frusemide in relation to breakfast was
carried out over a 3 month period in the medical wards ofthe Edinburgh Royal Infirmary.
Ofpatients who were prescribed a loop diuretic, 88 % were taking frusemide and 12 %
bumetanide. Of patients taking oral frusemide, 76 % were given it as a single early
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morning oral dose and the remainder took divided doses early in the morning and in the
afternoon. The majority ofpatients (83 %) took the early morning dose during or within
± 10 minutes of the start or finish of breakfast. This survey demonstrated the extent to
which the drugs are given in circumstances where efficacy may be compromised
5. In 10 patients receiving a single oral dose of at least 40 mg frusemide, significantly
higher mean peak plasma concentrations were obtained following administration oftheir
dose 2 h after breakfast (2.12 ± 0.95 mg/1) compared to administration at the usual time
i.e. close to breakfast (1.47 ± 0.76 mg/1). However no significant differences were found
in AUC() , total urinary recoveries or total natriuretic and diuretic response over 8 h
when frusemide was given 2 h after breakfast.
6. Following administration of 10, 40 and 80 mg oral frusemide to 8 healthy volunteers
on separate occasions, the normalised mean plasma concentrations (1.88 ± 0.63,
2.33 ± 0.54 and 2.13 ± 0.60 mg/1) and AUCq values were not significantly different
(2.84± 1.13, 3.54± 0.88 and 3.40± 0.84 mg.h/1). Time to peak concentrations also did
not differ significantly between the doses. Mean renal clearance values for the 10, 40 and
80 mg were 106.7 ± 39.8, 90.5 ± 32.0 and 99.0 ± 33.2 ml/min. These values were not
significantly different. Hourly renal clearances for all doses were constant over 8 h.
Frusemide does not exhibit dose-dependent absorption or clearance over the dose range
10 to 80 mg.
7. The mean renal clearance of frusemide was significantly reduced when administered in
a dose of40 mg together with 2.4 g intravenous benzylpenicillin in 8 healthy volunteers
(103.0 ± 15.9 for frusemide alone versus 83.6 ± 17.4 ml/min for frusemide + penicillin).
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This interaction could only be demonstrated during the first 2 h. Similarly, the urinary
excretion rate of frusemide was correspondingly reduced over the first hour following
administration with benzylpenicillin. The mean nonrenal clearance, plasma half-life,
volume of distribution and AUC of frusemide were not altered by penicillin.
Penicillin also had no effect on total sodium, potassium and water excretion
8. Another study was carried out in 8 healthy volunteers to compare the disposition and
diuretic and natriuretic response offrusemide given as a single oral dose of40 mg and as
5 mg every h for 8 h. The AUC() ]()| (2.89 ± 0.66 to 2.25 ±0.32 mg.h/1) and total urinary
recovery offrusemide (18.3 ±3.3 to 16.4±3.0 mg) were significantly reduced following
repeated dosing with 5 mg every h for 8 h compared to the single 40 mg dose. Despite
these results there was a tendency towards higher urinary sodium following the repeated
doses although the difference was not significant. A sustained release preparation of
oral frusemide would thus offer no advantage over a conventional tablet. However
taken together, these studies suggest that the time course of absorption and renal













Reason for Diuretic Treatment
r
238
List of other drugs patient is receiving:

















Has dose been changed since admission?;




relation to nearest meal:
Time taken in




Was patient taking the same diuretic at home?;
Yes / No


























































































































































































































































10min.beforer akfast Straightfterbre kfast 10min.beforer akfast 3min.afterbreakfast Straightafterbre kfas 5min.beforer akfast&6pm 5min.beforer akfast&4pm Withbreakfast 5min.beforer akfast 15min.afterbreakfast Withbreakfast&4pm Straightafterbre kfas Justbeforer akfast&6pm 15min.afterbreakf st Withbreakfast Withbreakfast Withbreakfast&4pm Withbreakfast&4pm 5min.beforer akfast
No No No No No 50mgivonadmissiont4 ral No 3mgoralt2 80mgoralt120mg No No No No No No 120mgoralt80iv Onadmission8() givnfusedov r1 No 50mgivonadmissionto4oral No
Withbreakfastnd6pm
15min.beforer akfast&4pmNo
InspoonfuloporridgeN 15min.beforer akfastN 15min.beforer akfast40mgor lt8 15min.beforer akfast&6pmNo
























































































































































741MPulmonaryoedemaFrus mide80 gStraightaft rbre kfaslOOivonadm ssi ngr l 7567MHypertensionBum a ide2.5mgStraightaf erbre kfNo
Note:iv=intravenousdos ;CCF=congestiveardiacfa lur ;LVFlefve icul rf il r ;*intra ousdos
N>
On
Cimetidine800mgo ,Salbutamol2p ffsTemazeparlOmgon. AspirinEC300mgom,Enalapril5 gm,Gaviscon1 lasreq.,GTNs r yreq.,Trimethop i2(X)bdWa farin. Diazepam5mgo ,FeiTOussulph te200mbd,Foliccid5 gom,M thylD125d,Ran tidine300b . Nootherdrugs Amitriptylene75mgom,Bisacodyl2tabsbd,Codeinephosphat30 gqid,MetoclopramidelO8hou . Aspirin300mgom,Diazepam5 gom.Dilt aze9bd,GTN2spraysasreq.,1SMO0bd.Met prolol5d. Enalapril2()mg10pm,Ferroussulphate2 0bd,Glibencl id5 gom,Parac tam l0 gtd. Cimetidine400mg1 p ,Codydramol2every6h urs. Becotidebd,Digoxin250mg6pm,EnalaprillOmg10p . Amiloride5 gom.Amoxil250tid,Cimetidine801 p ,Paracetamolt bsseq. Aspirin75mgom.D goxin0,625m,Enalapr llO gom,GTN2sprayssreq.,Nifedipineqid. Diltiazem60mgbd,GTN2spraysasreq.,ISMOlO ,Tem zep mg10pm. AdalatLA30mgo ,Amiloride5 g,Aspirin75om,Digoxin25Paraceta ollg6hourly. Aspirin300mgo ,GTN2praysasreq.ISMOmgbd,Nifedi inelOd,Qu nsul h t30om. Coproxamol2labs6h urly,Dihydrocodeine30mgqi ,MetoclopramidelO8h u lyOx gen35%c ntinuous. Amiloride5 gom,Amoxycillin00mtid,Erythr m n5tid,Pa aceta ol2basreq,PrednisolonelO gom Salbuta ol.5b Amiloride5 gom,BecotidlOO gbd,Ipratropium500qid,Paracetamolg6hou lySalbut molgqi . Augmentintid,Coproxamol2x6hourly EnalaprillO gom, rythr mycin250qid,GTN,Mucogel20ml,Ranitidine15()b . Aspirin75mgom,AtenolollOOom,Enalapril1bd,Glibe se5 gom,Nitrazepam10p . Amiloride5 gom,Coproxa ol2tabs6-8h urlyGTNsp ays,Thy oxine150m. Amiloride5 gom,Aspirin75mom,Diltiazem90bd,GTN2spraysp ,ISMObd,Paraceta ollgqi . Amiloride5 gom.Amoxil500tid,Becotide2fXlpbd.D g x n1256pGTN,ISMOlO gbd,Vent linsprayq . Aspirin150mgo ,Becotide2puffsGTNspray .Vent linuffs.
Amiloride5 gom,spi in75Augmenti2tabsid,Copr xa ol4hourly. SlowK1tabid. Aspirin75mgo ,Digox0.125m,Enalapril20om. Amoxil500mgtid,roventqidCocodamo2tabsiEry hromycin500 gPul acortb ,Sennata6p . Aspirin75mgo ,tenolol50 ,Ranitidine150bd,Sl wKtab. Digoxin125mg2pm,Losec0Temazepam() g10 . Aspirin300mgom,Diltiazem6 mtid,Enalapril15 go I durom,Metoclopr midelO8hourly,Te aze10p . Amiodarone200mgom,Enalaprilmg,GTNspr ysasreq. Amiloride5 gom,Aspirin75mom,Bu cardBuccal,Coproxamol2x6hourly,D ltiazem60tid,GTN,Salb tamol.qid. Digoxin0.25mgom,Methylpatid,Paraceta ollh4-6hourly,TemazepaO g10p . Aspirin75mgo ,Cimetidine400bd,EnalaprillOom,GTN2spr ysp ,Qui ineul h te3 g10 m. Amiloride5 gom,Aspirin300mgom,Diltiazem6bd,GTN2spraysp . Adalal20mgbd,AllopurinolOOmom,Amiloride5 go ,Codei e3 MethylD a25tid O epraz le0o . Amalodipine5mgo ,ISMO40mbd.SlowK1t bbd,Thiora izine256p . Allopurinol300mgm,Amlodipine5 go , spirinom,Dig xi0.125om,Ena apr llOom,Gam anil,Phenobarb tone6 Flucloxacillin500mgqid,Penici linVid. Aspirin150mgom,ISMO20mgbd,LisinoprillOo . Amoxycillin250mgom,Captoprilmgtid,Paracet mollg6hourly. Augmentin1.2gtid,Coproxamol2x6hourly,Enalapril5m,GTN,Im d um,Nyst tilozengetid,V ncomycinbd. Aspirin150mgom,EnalaprillOmbd,GTN2raysasreq.,Parac tamol0.5g6hourly. Cimetidine400mgom,Digoxin62.5pom,Gavisco1 lasr q.,Gliquidone5 gom ISMOlObd. Digoxin0.125gom,ThioridazinelObd,Wh sky30 l6p . Amiloride5 gom,spi in75om,Paracetamollg4-6hourlySenn2tabs6p . Amiloride5 gom,Diltiazem60mlid,Glipizid10 g,GTN2sprays,ISMO4tid. AspirinEC3(K)mgom,Diltiazem90 gbd,Gavisco1 lsreq.,TN2sprays,ISMObd,SlowKt bsd.
PatientNo.Oth rprescribeddrugs 49Aspirin75mgom.Coproxamol2tabsid,GTN500psreq.,Met rololbd,Phenobarbitone3 gid. 50Aspirin75mgom,Enalapril20Glipiz delObd,GTNpraysasreq.,ISMOgbd,L ctulose1 ld. 51Captopril0mgom,Coproxamo2t bs6hou ly,S diumbic rbonatelgid,Temaze a0 g10 m. 52Lisinoprilmgom,Phenobarbitone30tid.Phe ytoi5,Salbutamol2puffsasreq. 53Aspirin300mgom,EnalaprillOm. 54Amoxycillin00mgtid,Aspirin75m,Enala l2om,Gli iz delO gbd,ISMO6p . 55Aspirin300mgom,Coproxamolasreq,Hyd alazi etid,Indometh c25 gt ,ISMObd,Nifedi inelOo . 56Amiodarone200mgbd,Aspiri3 om,Augmenlinltid,Bisacodyl5 g10pm,Coproxa l4-hourly,O epr zole2o . 57Calcichew500mgbd,Cephalexin,G iquidone3 mgb Sod uicarbonatlOO6p ,Vent lin2mgd. 58AspirinEC300mgom.Codydramol2x6hourly,EnalaprilOom.En prilg6pm SlowKtab,Te azepal10pm. 59Captopril12.5mgtid,NifedipinelOmgb . 60Amiloride5 gom,Am xycillin250 gtid,Asp ri1Erythromyc n50qid. 61Aspirin75mgom,Captopril2bd.GTNspr ysasreq.,ISMO40 gbd,Paracet mollg. 62Enalapril5mgom,TemazepamlO10p ,Warfarinscharted. 63Adalatretard20mgbd,spirin300oGTNasr q.,ISMO,Paracet ollghourly. 64Diazepam2mg10pm,Digoxin0.125 g6pm,ISMO40bd,Nifed ine2bd,Paracetamollg-6hourly. 65Amiodarone200mg,A oxycilli5t ,spir n3 m,Captopr lgbISMO6oParacetamlg4-6hourly. 66Aspirin300mgo ,EnalaprillOmOxygensrequi ed. 67EnalaprillOmgoNyst tinyrup1mltid. 68Aspirin75mgom.Digoxin0.25m,Diltiaze60GTN2praysasreq.ISMOgbd,Parac ta llghou l 69Amitriptylene25mgbd,Augmenti1tabChlord zepoxidelODigoxin250ppSl wK600 . 70Aspirin300mgo ,Digoxi0.252pmGTN5 pasreq.ISMOgbd,Sl wKt b. 71Dihydrocodeine30mg6-8hourly,ISMO2b ,Sennatabsp ,lowKiTem zepamlO g10 . 72Aspirin5mgo ,Cyclimo ph5 giv.,Enalapril10p . 73Aspirin150mgom,Coproxamol2tabs6h urly.
74Amoxycillin5()0mgbd,spirin5m,Captopril2Diltiaze60tGTNinfusio ,ISMO. 75Captopril25mgtid,G viscon10 l4hourly,Surgam3 0bd.





A. Foods to avoid: (These contain a lot of salt)
Salted butter, salted margarine
Ordinary cheese
Bacon, ham, salami, sausages, black pudding
Tinned meat e.g. corned beef, spam, tongue, luncheon meat
Tinned fish e.g. sardines, tuna
Smoked fish e.g. kippers, golden cutlet (yellow haddock)
Meat and fish pastes
Tinned vegetables (some varieties e.g. Del Monte are now salt free and
therefore suitable)
Tinned and packet soups
Commercially prepared sauces and ketchups
Oxo, Bovril, Marmite, Soya sauce, stock cubes
Salted crisps, salted nuts
Salted biscuits e.g. Tuc, Cheddars
Health salts e.g. Andrews
B Foods to be taken freely:
Suitable meats: mince, stew, steak, chops, liver; roasting beef, lamb or pork;
chicken, turkey; whiting, haddock, plaice, cod, sole, herring.
Fruit - fresh, stewed and tinned
Vegetables - raw or cooked using a little salt
Potato - cooked with a little salt
Nuts - unsalted
Breakfast cereal
Rice and pasta (boiled with a little salt)
Unsalted butter and low salt margarine
Oil, cooking fat





Biscuits (avoid salty variety e.g. Tuc, Cheddar)
Ice cream, chocolate
Milk (not more than 1 pint per day)
Salt could be used in cooking but not sprinkled on the food afterwards (except on boiled
egg or cold meat or salad where salt cannot be incorporated in the cooking - a little salt
may be sprinkled on these items). Food taken with less salt than normal is improved by
the use ofherbs, spices, onion, garlic etc.
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List ofAbbreviations
Ae: Total amount ofdrug excreted
AUC: Area under the plasma concentration-time
C: Drug concentration
Cmax Peak plasma concentration
CL: Clearance
CLr: Renal clearance




hplc: High performance liquid chromatography
i.v.: Intravenous
k: Absorption rate constant
a
k : Distribution rate constant
d










Tmax: Time to peak plasma concentration
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